<SEC-DOCUMENT>0001193125-24-023367.txt : 20240205
<SEC-HEADER>0001193125-24-023367.hdr.sgml : 20240205
<ACCEPTANCE-DATETIME>20240205060532
ACCESSION NUMBER:		0001193125-24-023367
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240201
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240205
DATE AS OF CHANGE:		20240205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tyra Biosciences, Inc.
		CENTRAL INDEX KEY:			0001863127
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				831476348
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40800
		FILM NUMBER:		24593821

	BUSINESS ADDRESS:	
		STREET 1:		2656 STATE STREET
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92008
		BUSINESS PHONE:		(619) 728-4760

	MAIL ADDRESS:	
		STREET 1:		2656 STATE STREET
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92008
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d620082d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:tyra="http://tyra.bio/20240201" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-334">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-02-01_to_2024-02-01">0001863127</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="tyra-20240201.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-02-01_to_2024-02-01"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-02-01</xbrli:startDate> <xbrli:endDate>2024-02-01</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-345">8-K</ix:nonNumeric></span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">PURSUANT TO SECTION 13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF THE SECURITIES EXCHANGE ACT OF 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-02-01_to_2024-02-01" format="ixt:datemonthdayyearen" id="ixv-346">February&#160;1, 2024</ix:nonNumeric></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-347">TYRA BIOSCIENCES, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-02-01_to_2024-02-01" format="ixt-sec:stateprovnameen" id="ixv-348">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-349">001-40800</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-350">83-1476348</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction<br/>of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br/>File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(I.R.S. Employer<br/>Identification No.)</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom" colspan="3"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-351">2656 State Street</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-352">Carlsbad</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-02-01_to_2024-02-01" format="ixt-sec:stateprovnameen" id="ixv-353">California</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-354">92008</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top" colspan="3"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-355">(619)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-356">728-4760</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-02-01_to_2024-02-01" format="ixt-sec:boolballotbox" id="ixv-357">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-02-01_to_2024-02-01" format="ixt-sec:boolballotbox" id="ixv-358">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-02-01_to_2024-02-01" format="ixt-sec:boolballotbox" id="ixv-359">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-02-01_to_2024-02-01" format="ixt-sec:boolballotbox" id="ixv-360">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-361">Common stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-362">TYRA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-02-01_to_2024-02-01" format="ixt-sec:exchnameen" id="ixv-363">Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Sec.230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(Sec.240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-02-01_to_2024-02-01" format="ixt-sec:boolballotbox" id="ixv-364">&#9746;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2024-02-01_to_2024-02-01" format="ixt-sec:boolballotbox" id="ixv-365">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">On February&#160;1, 2024, Tyra Biosciences, Inc. (the Company) entered into a securities purchase agreement (the Purchase Agreement) with the purchasers named therein (the Purchasers), for the private placement (the Private Placement) of (i) 9,286,023 shares (the Shares) of the Company&#8217;s common stock, par value $0.0001 per share (the Common Stock), at a price of $13.01 per Share, and (ii)&#160;with respect to certain Purchasers, <span style="white-space:nowrap">pre-funded</span> warrants to purchase an aggregate of 6,087,230 shares of Common Stock (the <span style="white-space:nowrap">Pre-Funded</span> Warrants) in lieu of shares of Common Stock, at a purchase price of $13.009 per <span style="white-space:nowrap">Pre-Funded</span> Warrant (the shares of Common Stock issuable upon exercise of the <span style="white-space:nowrap">Pre-Funded</span> Warrants, the Warrant Shares). The aggregate gross proceeds for the Private Placement are expected to be approximately $200&#160;million, before deducting offering expenses. The Private Placement is expected to close on February&#160;6, 2024, subject to customary closing conditions. The Private Placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the &#8220;Minimum Price&#8221; requirement (as defined in the Nasdaq rules). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company intends to use the net proceeds from the Private Placement to advance the clinical development of <span style="white-space:nowrap">TYRA-300</span> and <span style="white-space:nowrap">TYRA-200,</span> to advance its preclinical programs, and for drug discovery, working capital and general corporate purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Each <span style="white-space:nowrap">Pre-Funded</span> Warrant will have an exercise price of $0.001 per share of Common Stock, will be immediately exercisable on the date of issuance and will not expire. Under the terms of the <span style="white-space:nowrap">Pre-Funded</span> Warrants, the Company may not effect the exercise of any <span style="white-space:nowrap">Pre-Funded</span> Warrant, and a holder will not be entitled to exercise any portion of any <span style="white-space:nowrap">Pre-Funded</span> Warrant, which, upon giving effect to such exercise, would cause a holder (together with its affiliates) to own more than a specified beneficial ownership limitation of either 4.99%, 9.99% or 19.99% (as selected by such holder prior to the issuance of the <span style="white-space:nowrap">Pre-Funded</span> Warrant) of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the <span style="white-space:nowrap">Pre-Funded</span> Warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 19.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice is delivered to the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The exercise price and the number of shares of Common Stock issuable upon exercise of each <span style="white-space:nowrap">Pre-Funded</span> Warrant will be subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">In the event of certain fundamental transactions (as described in the <span style="white-space:nowrap">Pre-Funded</span> Warrants), a holder of <span style="white-space:nowrap">Pre-Funded</span> Warrants will be entitled to receive, upon exercise of the <span style="white-space:nowrap">Pre-Funded</span> Warrants, the kind and amount of securities, cash or property that such holder would have received had they exercised in full the <span style="white-space:nowrap">Pre-Funded</span> Warrants immediately prior to such fundamental transaction without regard to any limitations on exercise contained in the <span style="white-space:nowrap">Pre-Funded</span> Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Pursuant to the Purchase Agreement, the Company agreed to file a registration statement with the Securities and Exchange Commission (the SEC) within 45 days after the closing of the Private Placement (subject to certain exceptions) for purposes of registering the resale of the Shares and the Warrant Shares, to use its reasonable best efforts to have such registration statement declared effective within the time period set forth in the Purchase Agreement, and to keep such registration statement effective until the earliest of (i)&#160;the time as all of the Shares and Warrant Shares purchased by the Purchasers pursuant to the terms of the Purchase Agreement have been sold pursuant to the registration statement, or (ii)&#160;such time as the Shares and Warrant Shares become eligible for resale by <span style="white-space:nowrap">non-affiliates</span> without any volume limitations or other restrictions pursuant to Rule 144 under the Securities Act of 1933, as amended (the Securities Act). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Purchase Agreement, the Company and the Company&#8217;s executive officers and directors agreed not to sell or otherwise dispose of any Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, for 60 days (or with respect to the Company, the earlier of 60 days after the closing or the effective date of the registration statement). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The Purchase Agreement contains customary representations, warranties and agreements by the Company, indemnification obligations of the Company and the Purchasers, including for liabilities under the Securities Act, and other obligations of the parties. The representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of such Purchase Agreement and are made as of specific dates; are solely for the benefit of the parties (except as specifically set forth therein); may be subject to qualifications and limitations agreed upon by the parties in connection with negotiating the terms of the Purchase Agreement, instead of establishing matters as facts; and may be subject to standards of materiality and knowledge applicable to the contracting parties that differ from those applicable to the investors generally. Investors should not rely on the </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">
representations, warranties and covenants or any description thereof as characterizations of the actual state of facts or condition of the Company. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The Private Placement is exempt from the registration requirements of the Securities Act pursuant to the exemption for transactions by an issuer not involving any public offering under Section&#160;4(a)(2) of the Securities Act and Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions under applicable state laws. The Purchasers represented that they were accredited investors within the meaning of Rule 501 of Regulation D and were acquiring the securities for investment only and with no present intention of distributing any of such securities or any arrangement regarding the distribution thereof. The securities were offered without any general solicitation by the Company or its representatives. The securities sold and issued in the Private Placement will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The foregoing description of the Purchase Agreement and <span style="white-space:nowrap">Pre-Funded</span> Warrant does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement and form of <span style="white-space:nowrap">Pre-Funded</span> Warrant, which are filed as Exhibit 10.1 and 4.1, respectively, to this Current Report on Form <span style="white-space:nowrap">8-K</span> and incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;3.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Unregistered Sales of Equity Securities. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The disclosures set forth in Item 1.01 above are incorporated in this Item 3.02. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">On February&#160;2, 2024, the Company issued a press release announcing that it has entered into the Purchase Agreement. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">The information contained in this Item 7.01, including in Exhibit 99.1 hereto, is being &#8220;furnished&#8221; and shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;No&#8195;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d620082dex41.htm">Form of <span style="white-space:nowrap">Pre-Funded</span> Warrant </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d620082dex101.htm">Securities Purchase Agreement, dated February&#160;1, 2024, by and between Tyra Biosciences, Inc. and each of the purchasers party thereto. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d620082dex991.htm">Press Release dated February&#160;2, 2024. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Statements in this report that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements regarding the completion of the Private Placement and the anticipated use of proceeds therefrom, and related to the anticipated filing of a registration statement to cover the resale of Shares and Warrant Shares. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the Private Placement, as well as risks and uncertainties inherent in the Company&#8217;s business described in the Company&#8217;s prior press releases and the Company&#8217;s filings with the SEC, including under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s annual report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2022 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof, except as required by law. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">TYRA BIOSCIENCES, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: February&#160;5, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ali Fawaz</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Ali Fawaz</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">General Counsel and Secretary</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>d620082dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;), OR ANY
OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE
REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED, HYPOTHECATED OR OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO A TRANSACTION WHICH IS EXEMPT FROM, OR NOT SUBJECT TO,
SUCH REGISTRATION, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS, AND, IN THE CASE OF A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, THE HOLDER WILL NOTIFY ANY SUBSEQUENT PURCHASER OF THE SECURITIES EVIDENCED BY
THIS CERTIFICATE FROM IT OF SUCH RESALE RESTRICTIONS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT TO PURCHASE
COMMON STOCK </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TYRA BIOSCIENCES, INC.</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Number of Shares: [&#8195;&#8195;&#8195;&#8195;] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(subject to adjustment) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant No. <U>&#8195;</U>&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Original&nbsp;Issue&nbsp;Date:&nbsp;[&#8195;&#8195;&#8195;&#8195;],&nbsp;2024</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tyra Biosciences, Inc.,</B> a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), hereby certifies that, for good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [&#8195;] or its registered assigns (the &#147;<B><I>Holder</I></B>&#148;), is entitled, subject to the terms set forth below, to purchase from the Company up
to a total of [&#8195;] shares of common stock, $0.0001 par value per share (the &#147;<B><I>Common Stock</I></B>&#148;), of the Company (each such share, a &#147;<B><I>Warrant Share</I></B>&#148; and all such shares, the &#147;<B><I>Warrant
Shares</I></B>&#148;) at an exercise price per share equal to $0.001 per share (as adjusted from time to time as provided in <U>Section</U><U></U><U>&nbsp;9</U> herein, the &#147;<B><I>Exercise Price</I></B>&#148;), upon surrender of this Warrant to
Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#147;<B><I>Warrant</I></B>&#148;) at any time and from time to time on or after the date hereof (the &#147;<B><I>Original
Issue Date</I></B>&#148;), subject to the following terms and conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <I>Definitions</I>. For purposes of this Warrant, the following terms shall
have the following meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B><I>Affiliate</I></B>&#148; means, with respect to any Person, any other Person directly or
indirectly controlled by, controlling or under common control with, such Person, but only for so long as such control shall continue. For purposes of this definition, &#147;control&#148; (including, with correlative meanings, &#147;controlled
by&#148;, &#147;controlling&#148; and &#147;under common control with&#148;) means, with respect to a Person, possession, direct or indirect, of (i)&nbsp;the power to direct or cause direction of the management and policies of such Person (whether
through ownership of securities or partnership or other ownership interests, by contract or otherwise), or (ii)&nbsp;at least 50% of the voting securities (whether directly or pursuant to any option, warrant or other similar arrangement) or other
comparable equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Attribution Parties</I></B>&#148; means, collectively, the following Persons and entities:
(i)&nbsp;any direct or indirect Affiliates of the Holder, (ii)&nbsp;any Person acting or who could be deemed to be acting as a Group together with the Holder or any Attribution Parties and (iii)&nbsp;any other Persons whose beneficial ownership of
the Common Stock would or could be aggregated with the Holder&#146;s and/or any other Attribution Parties for purposes of Section&nbsp;13(d) or Section&nbsp;16 of the Exchange Act. For clarity, the purpose of the foregoing is to subject collectively
the Holder and all other Attribution Parties to the Maximum Percentage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B><I>Closing Sale Price</I></B>&#148; means, for any
security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg Financial Markets, or, if such Principal Trading Market begins to operate on an extended hours basis and does
not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade price of such security in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
bulletin board for such security as reported by Bloomberg Financial Markets, or if no last trade price is reported for such security by Bloomberg Financial Markets, the average of the bid and ask
prices of any market makers for such security as reported in the OTC Link or &#147;pink sheets&#148; by OTC Markets Group Inc. as of 4:00 P.M., New York City time on such date. If the Closing Sale Price cannot be calculated for a security on a
particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair
market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors&#146; determination shall be binding upon all parties absent demonstrable error.
All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B><I>Commission</I></B>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B><I>Group</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;13(d) of the Exchange Act, and all related rules,
regulations and jurisprudence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B><I>Person</I></B>&#148; means an individual, a limited liability company, a partnership, a
joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B><I>Principal Trading Market</I></B>&#148; means the national securities exchange or other trading market on which the Common
Stock is primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)
&#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) &#147;<B><I>Standard Settlement
Period</I></B>&#148; means the standard settlement period, expressed in a number of Trading Days, for the Principal Trading Market with respect to the Common Stock that is in effect on the date of delivery of an applicable Exercise Notice, which as
of the Original Issue Date was &#147;T+2.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) &#147;<B><I>Trading Day</I></B>&#148; means any weekday on which the Principal
Trading Market is normally open for trading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) &#147;<B><I>Transfer Agent</I></B>&#148; means Computershare Trust Company, N.A., the
Company&#146;s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <I>Issuance of Securities;
Registration of Warrants</I>. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#147;<B><I>Warrant Register</I></B>&#148;), in the name of the record Holder (which shall include
the initial Holder or, as the case may be, any assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of
any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <I>Registration of
Transfers</I>. Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant,
and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &#147;<B><I>New Warrant</I></B>&#148;)
evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the
New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer
Agent to, prepare, issue and deliver at the Company&#146;s own expense any New Warrant under this <U>Section</U><U></U><U>&nbsp;3</U>. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the
owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <I>Exercise of Warrants</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant (including
Section&nbsp;11) at any time and from time to time on or after the Original Issue Date, and such rights shall not expire. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Holder may exercise this Warrant by delivering to the Company (i)&nbsp;an exercise
notice, in the form attached as <U>Schedule 1</U> hereto (the &#147;<B><I>Exercise Notice</I></B>&#148;), completed and duly signed, and (ii)&nbsp;payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being
exercised (which may take the form of a &#147;cashless exercise&#148; if so indicated in the Exercise Notice pursuant to <U>Section</U><U></U><U>&nbsp;10</U> below), and the date on which the last of such items is delivered to the Company (as
determined in accordance with the notice provisions hereof) is an <B>&#147;</B><B><I>Exercise Date</I></B>.&#148; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of
the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. <B></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <I>Delivery of Warrant Shares</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Upon
exercise of this Warrant, the Company shall promptly (but in no event later than the number of Trading Days comprising the Standard Settlement Period following the Exercise Date), upon the request of the Holder, credit such aggregate number of
shares of Common Stock specified by the Holder in the Exercise Notice and to which the Holder is entitled pursuant to such exercise (the &#147;<B><I>Exercise Shares</I></B>&#148;) to the Holder&#146;s or its designee&#146;s balance account with The
Depository Trust Company (&#147;<B><I>DTC</I></B>&#148;) through its Deposit Withdrawal At Custodian system, or if the Transfer Agent is then a participant in the DTC Fast Automated Securities Transfer Program (the &#147;<B><I>FAST
Program</I></B>&#148;) and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or the resale of such Warrant Shares by the Holder or (B)&nbsp;the Exercise Shares are eligible for resale by
the Holder without volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions pursuant to Rule 144 promulgated under the Securities Act (assuming cashless exercise of this Warrant). If the
Transfer Agent is not a member of the FAST Program or if (A)&nbsp;and (B) above are not true, the Transfer Agent will either (i)&nbsp;record the Exercise Shares in the name of the Holder or its designee on the certificates reflecting the Exercise
Shares with an appropriate legend regarding restriction on transferability, which shall be issued and dispatched by overnight courier to the address as specified in the Exercise Notice, and on the Company&#146;s share register or (ii)&nbsp;issue
such Exercise Shares in the name of the Holder or its designee in restricted book-entry form in the Company&#146;s share register. The Holder, or any Person so designated by the Holder to receive Warrant Shares, shall be deemed to have become the
holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&#146;s DTC account, the date of the book entry positions or the date of delivery of the certificates evidencing
such Exercise Shares, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If the Company fails to deliver to the Holder or its designee Exercise Shares in the manner
required pursuant to <U>Section</U><U></U><U>&nbsp;5(a)</U> within the Standard Settlement Period following the Exercise Date (other than a failure solely caused by incorrect or incomplete information provided by the Holder to the Company) and the
Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#147;<B><I><FONT
STYLE="white-space:nowrap">Buy-In</FONT></I></B>&#148;) but did not receive within the Standard Settlement Period, then the Company shall, within two (2)&nbsp;Trading Days after the Holder&#146;s request, (1)&nbsp;pay in cash to the Holder the
amount, if any, by which (x)&nbsp;the Holder&#146;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the <FONT STYLE="white-space:nowrap">Buy-In</FONT> exceeds (y)&nbsp;the amount obtained
by multiplying (A)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (B)&nbsp;the Closing Sale Price of a share of Common Stock on the Exercise Date, and
(2)&nbsp;at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the
number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) To the extent permitted by law and subject to <U>Section</U><U>&nbsp;5(b)</U>, the Company&#146;s obligations to issue and deliver Warrant
Shares in accordance with and subject to the terms hereof (including the limitations set forth in <U>Section</U><U></U><U>&nbsp;11</U> below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same,
any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the
Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the
Holder in connection with the issuance of Warrant Shares. Subject to <U>Section</U><U>&nbsp;5(b)</U>, nothing herein shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the Company&#146;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <I>Charges, Taxes and Expenses</I>. Issuance and delivery for shares of Common Stock upon exercise of this Warrant shall be made without charge to the
Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company;
<I>provided</I>, <I>however</I>, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any Warrant Shares or the Warrants in a name other than that of the Holder or an
Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <I>Replacement of Warrant</I>. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and
substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each
case, a customary and reasonable contractual indemnity, if requested by the Company. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition
precedent to the Company&#146;s obligation to issue the New Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <I>Reservation of Warrant Shares</I>. The Company covenants that it will, at all
times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this
Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder
(taking into account the adjustments and restrictions of <U>Section</U><U></U><U>&nbsp;9</U>). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in
accordance with the terms hereof, be duly authorized, validly issued, and fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Company will take all such action as may be reasonably necessary to assure that such shares of
Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further
covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <I>Certain Adjustments</I>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to
time as set forth in this <U>Section</U><U></U><U>&nbsp;9</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and Splits</U>. If the Company, at any time while
this Warrant is outstanding, (i)&nbsp;pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the
Original Issue Date or as amended, that is payable in shares of Common Stock, (ii)&nbsp;subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii)&nbsp;combines its outstanding shares of Common Stock into
a smaller number of shares of Common Stock or (iv)&nbsp;issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company, then in each such case the Exercise Price shall be multiplied by a fraction, the
numerator of which shall be the number of shares of Common Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made
pursuant to clause (i)&nbsp;of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, <I>provided, however</I>, that if such record date shall
have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly as of the close of business on such record date and thereafter the Exercise Price shall be adjusted pursuant to this
paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii), (iii) or (iv)&nbsp;of this paragraph shall become effective immediately after the effective date of such subdivision, combination or issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Pro Rata Distributions</U>. If, on or after the Original Issue Date, the Company shall declare or make any dividend or other pro rata
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property, options,
evidence of indebtedness or any other assets by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction, but, for the avoidance of doubt, excluding any distribution of shares of
Common Stock subject to <U>Section</U><U></U><U>&nbsp;9(a)</U>, any distribution of Purchase </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Rights (as defined below) subject to <U>Section</U><U></U><U>&nbsp;9(c)</U> and any Fundamental Transaction (as defined below) subject to <U>Section</U><U></U><U>&nbsp;9(d))</U> (a
&#147;<B><I>Distribution</I></B>&#148;) then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of
Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage (as defined below)) immediately before the date on
which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<I>provided</I>, that to the extent
that the Holder&#146;s right to participate in any such Distribution would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution to such
extent (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Distribution (and beneficial ownership) to such extent) and such portion of such Distribution shall be held in abeyance for the benefit of
the Holder until such time or times as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such Distribution (and any Distributions
declared or made on such initial Distribution or on any subsequent Distribution held similarly in abeyance) to the same extent as if there had been no such limitation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Purchase Rights</U>. If at any time on or after the Original Issue Date, the Company grants, issues or sells any Options, Convertible
Securities or rights to purchase stock, warrants, securities or other property, in each case pro rata to the record holders of any class of Common Stock (the &#147;<B><I>Purchase Rights</I></B>&#148;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to
any limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record
is taken, the date as of which the record holders of Common Stock are to be determined for the grant, issuance or sale of such Purchase Rights (<I>provided</I>, that to the extent that the Holder&#146;s right to participate in any such Purchase
Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right to such extent (and shall not be entitled to beneficial ownership of
such Common Stock as a result of such Purchase Right (and beneficial ownership) to such extent) and such Purchase Right to such extent shall be held in abeyance for the benefit of the Holder until such time or times as its right thereto would not
result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any
subsequent Purchase Right to be held similarly in abeyance) to the same extent as if there had been no such limitation). As used in this Section&nbsp;9(c), (i) &#147;Options&#148; means any rights, warrants or options to subscribe for or purchase
shares of Common Stock or Convertible Securities and (ii) &#147;Convertible Securities&#148; mean any stock or securities (other than Options) directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding (i)&nbsp;the Company effects any merger or
consolidation of the Company with or into another Person, in which the Company is not the surviving entity or in which the stockholders of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50%
of the voting power of the surviving entity immediately after such merger or consolidation, (ii)&nbsp;the Company effects any sale to another Person of all or substantially all of its assets in one or a series of related transactions,
(iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such
other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the voting power of the capital stock of the Company (except for any such transaction in which the
stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v)&nbsp;the Company effects any reclassification of the Common
Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by
<U>Section</U><U></U><U>&nbsp;9(a)</U> above) (in any such case, a &#147;<B><I>Fundamental Transaction</I></B>&#148;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same
amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the
&#147;<B><I>Alternate Consideration</I></B>&#148;). The Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the
Alternate Consideration is solely cash and the Company provides for the simultaneous &#147;cashless exercise&#148; of this Warrant pursuant to <U>Section</U><U></U><U>&nbsp;10</U> below or (ii)&nbsp;prior to or simultaneously with the consummation
thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing
provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (d)&nbsp;shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Number of Warrant Shares</U>. Simultaneously with any adjustment to the Exercise Price pursuant to <U>Section</U><U></U><U>&nbsp;9</U>,
the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of
Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Calculations</U>.
All calculations under this <U>Section</U><U></U><U>&nbsp;9</U> shall be made to the nearest <FONT STYLE="white-space:nowrap">one-tenth</FONT> of one cent or the nearest share, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Notice of Adjustments</U>. Upon the occurrence of each adjustment pursuant to this <U>Section</U><U></U><U>&nbsp;9</U>, the Company at
its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted
Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such
adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Transfer Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company (i)&nbsp;declares a dividend or any other
distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary,
(ii)&nbsp;authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company,
then the Company shall deliver to the Holder a notice of such transaction at least ten (10)&nbsp;days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect
to such transaction; <I>provided, however</I>, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is
outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by <U>Section</U><U></U><U>&nbsp;9(d)</U>, other than a Fundamental Transaction
under clause (iii)&nbsp;of <U>Section</U><U></U><U>&nbsp;9(d),</U> the Company shall deliver to the Holder a notice of such Fundamental Transaction at least thirty (30)&nbsp;days prior to the date such Fundamental Transaction is consummated. Holder
agrees to maintain any information disclosed pursuant to this <U>Section</U><U></U><U>&nbsp;9(h)</U> in confidence until such information is publicly available, and shall comply with applicable law with respect to trading in the Company&#146;s
securities following receipt of any such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <I>Payment of Exercise Price</I>. Notwithstanding anything contained herein to the contrary,
the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a &#147;cashless exercise&#148;, in which event the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected
pursuant to Section&nbsp;3(a)(9) of the Securities Act, as determined as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">X = Y <FONT STYLE="white-space:nowrap">[(A-B)/A]</FONT>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">where: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;X&#148;
equals the number of Warrant Shares to be issued to the Holder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Y&#148; equals the total number of Warrant Shares with respect to
which this Warrant is then being exercised; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;A&#148; equals the Closing Sale Price of the shares of Common Stock (as reported by
Bloomberg Financial Markets) as of the Trading Day on the date immediately preceding the Exercise Date; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;B&#148; equals the Exercise Price then in effect for the applicable Warrant Shares at
the time of such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant
Shares issued in a &#147;cashless exercise&#148; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued
(<I>provided</I> that the Commission continues to take the position that such treatment is proper at the time of such exercise). In the event that a registration statement registering the issuance of Warrant Shares is, for any reason, not effective
at the time of exercise of this Warrant, then the Warrant may only be exercised through a cashless exercise, as set forth in this <U>Section</U><U>&nbsp;10</U>. If the Warrant Shares are issued in such a cashless exercise, the Company acknowledges
and agrees that, in accordance with Section&nbsp;3(a)(9) of the Securities Act, the Exercise Shares issued in such exercise shall take on the registered characteristics of the Warrants being exercised and may be tacked on to the holding period of
the Warrants being exercised. Except as set forth in Section&nbsp;5(b) <FONT STYLE="white-space:nowrap">(Buy-In</FONT> remedy) and Section&nbsp;12 (payment of cash in lieu of fractional shares), in no event will the exercise of this Warrant be
settled in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <I>Limitations on Exercise</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect the exercise of any portion of this Warrant, and
the Holder of the Warrant shall not have the right to exercise any portion of the Warrant, and any such exercise shall be null and void ab initio and treated as if the exercise had not been made, to the extent that immediately prior to or following
such exercise, the Holder, together with the Attribution Parties, beneficially owns or would beneficially own as determined in accordance with Section&nbsp;13(d) of the Exchange Act and the rules promulgated thereunder, in excess of
[4.99%][9.99%][19.99%] (the &#147;<B><I>Maximum Percentage</I></B>&#148;) of the Common Stock that would be issued and outstanding following such exercise. For purposes of calculating beneficial ownership for determining whether the Maximum
Percentage is or will be exceeded, the aggregate number of shares of Common Stock held and/or beneficially owned by the Holder together with the Attribution Parties, shall include the number of shares of Common Stock held and/or beneficially owned
by the Holder together with the Attribution Parties plus the number of shares of Common Stock issuable upon exercise of the relevant Warrant with respect to which the determination is being made but shall exclude the number of shares of Common Stock
which would be issuable upon (i)&nbsp;exercise of the remaining, unexercised Warrant held and/or beneficially owned by the Holder or the Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised or unconverted portion of any other
securities of the Company held and/or beneficially owned by such Holder or any Attribution Party (including, without limitation, any convertible notes, convertible stock or warrants) that are subject to a limitation on conversion or exercise
analogous to the limitation contained herein. For purposes of this <U>Section</U><U></U><U>&nbsp;11(a)</U>, beneficial ownership of the Holder or the Attribution Parties shall, except as set forth in the immediately preceding sentence, be calculated
and determined in accordance with Section&nbsp;13(d) of the Exchange Act and the rules promulgated thereunder. For purposes of the Warrant, in determining the number of outstanding shares of Common Stock, a Holder of the Warrant may rely on the
number of outstanding shares of Common Stock as reflected in (1)&nbsp;the Company&#146;s most recent Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> or other public filing with the Commission, as the case may be, (2)&nbsp;a more recent public announcement by the Company or (3)&nbsp;any other notice by the Company or the Transfer Agent setting forth the
number of shares of Common Stock outstanding (such issued and outstanding shares, the &#147;<B><I>Reported Outstanding Share Number</I></B>&#148;). For any reason at any time, upon the written or oral request of the Holder, the Company shall within
one (1)&nbsp;Business Day confirm orally and in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. The Holder shall disclose to the Company the number of shares of Common Stock that it, together with
the Attribution Parties holds and/or beneficially owns and has the right to acquire through the exercise of derivative securities and any limitations on exercise or conversion analogous to the limitation contained herein contemporaneously or
immediately prior to submitting an Exercise Notice for the relevant Warrant. If the Company receives an Exercise Notice from the Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding
Share Number, the Company shall (i)&nbsp;notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Exercise Notice would otherwise cause the Holder&#146;s, together with the Attribution
Parties&#146;, beneficial ownership, as determined pursuant to this Section&nbsp;11(a), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of Warrant Shares to be purchased pursuant to such Exercise Notice (the
number of shares by which such purchase is reduced, the &#147;<B><I>Reduction Shares</I></B>&#148;) and (ii)&nbsp;as soon as reasonably practicable, the Company shall return to the Holder any exercise price paid by the Holder for the Reduction
Shares. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and the Attribution
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Parties since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of Common Stock to the Holder upon exercise of this Warrant results in the
Holder, together with the Attribution Parties, being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section&nbsp;13(d) of the Exchange Act), the
number of shares so issued by which the Holder&#146;s, together with the Attribution Parties&#146;, aggregate beneficial ownership exceeds the Maximum Percentage (the &#147;<B><I>Excess Shares</I></B>&#148;) shall be deemed null and void and shall
be cancelled ab initio, and the Holder and/or the Attribution Parties shall not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the
Company shall return to the Holder the exercise price paid by the Holder for the Excess Shares. By written notice to the Company, a Holder of the Warrant may from time to time increase or decrease the Maximum Percentage to any other percentage not
in excess of 19.99% specified in such notice; <I>provided </I>that any increase in the Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered to the Company and shall not negatively affect any
partial exercise effected prior to such change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) This <U>Section</U><U></U><U>&nbsp;11</U> shall not restrict the number of shares of
Common Stock which a Holder or the Attribution Parties may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder or the Attribution Parties may receive in the event of a Fundamental
Transaction as contemplated in <U>Section</U><U></U><U>&nbsp;9(d)</U> of this Warrant. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be
beneficially owned by the Holder or the Attribution Parties for any purpose including for purposes of Section&nbsp;13(d) of the Exchange Act and the rules promulgated thereunder or Section&nbsp;16 of the Exchange Act and the rules promulgated
thereunder, including Rule <FONT STYLE="white-space:nowrap">16a-1(a)(1).</FONT> No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any
subsequent determination of exercisability. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of <U>Section</U><U></U><U>&nbsp;11(a)</U> to the extent necessary to
correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in <U>Section</U><U></U><U>&nbsp;11(a)</U> or to make changes or supplements necessary or
desirable to properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Warrant.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <I>No Fractional Shares</I>. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares
that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <I>Notices</I>. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice)
shall be in writing and shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> at the <FONT
STYLE="white-space:nowrap">e-mail</FONT> address specified in the books and records of the Transfer Agent prior to 5:30 P.M., New York City time, on a Trading Day, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or
communication is delivered via confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address specified in the books and records of the Transfer Agent on a day that is not a Trading Day or
later than 5:30 P.M., New York City time, on any Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv)&nbsp;upon actual
receipt by the Person to whom such notice is required to be given, if by hand delivery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <I>Warrant Agent</I>. The Company shall initially serve as
warrant agent under this Warrant. Upon thirty (30)&nbsp;days&#146; notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any
consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor
warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#146;s last
address as shown on the Warrant Register. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <I>Miscellaneous</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Rights as a Stockholder</U>. Except as otherwise set forth in this Warrant, the Holder, solely in such Person&#146;s capacity as a
holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such
Person&#146;s capacity as the Holder of this Warrant, any of the rights of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger,
amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise
of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such
liabilities are asserted by the Company or by creditors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Authorized Shares</U>. (i)&nbsp;Except and to the extent
as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking
of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a)&nbsp;not increase the par value of any
Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (b)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid
and <FONT STYLE="white-space:nowrap">non-assessable</FONT> Warrant Shares upon the exercise of this Warrant, and (c)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body
having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) Before taking any action which
would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any
public regulatory body or bodies having jurisdiction thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and Assigns</U>. Subject to compliance with applicable
securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on
and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal
or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment and Waiver</U>. Except as otherwise provided herein, the provisions of the Warrants may be amended and the Company may take
any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions
contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Governing Law; Jurisdiction</U>. This Warrant shall be governed by and interpreted in accordance with the
substantive laws of the State of New York, without regard to its or any other jurisdiction&#146;s choice of law rules. Any and all disputes arising out of, concerning, or related to this Warrant, or to the construction, validity, enforcement and
interpretation thereof, shall be referred to and resolved by the federal courts located in New York, New York or, to the extent no such court has subject matter jurisdiction, the state courts of the State of New York located in New York, New York
(the &#147;<B><I>Specified Courts</I></B>&#148;). Each of the Company and the Holder irrevocably and unconditionally submits to the exclusive jurisdiction of the Specified Courts, waives any objection to the laying of venue of any suit, action or
proceeding brought in such courts and waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY
CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS WARRANT. THE SCOPE OF THIS WAIVER IS INTENDED TO <FONT STYLE="white-space:nowrap">BE&nbsp;ALL-ENCOMPASSING&nbsp;OF</FONT> ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE
TO THE THIS WARRANT. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE COMPANY AND THE HOLDER AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH OF THE COMPANY AND THE HOLDER HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY
HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Headings</U>. The headings herein are for convenience only, do not constitute a part
of this Warrant and shall not be deemed to limit or affect any of the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. In case any one or more
of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the
Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its
authorized officer as of the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TYRA BIOSCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1<U> </U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF EXERCISE NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To be executed by the Holder to purchase shares of Common Stock under the Warrant] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) The undersigned is the Holder of
Warrant No. __ (the &#147;Warrant&#148;) issued by <B>TYRA BIOSCIENCES, INC.</B>, a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth
in the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) The undersigned hereby exercises its right to purchase Warrant Shares pursuant to the Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) The Holder intends that payment of the Exercise Price shall be made as (check one): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#9744; Cash Exercise </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#9744;
&#147;Cashless Exercise&#148; under Section&nbsp;10 of the Warrant </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) If the Holder has elected a Cash Exercise, the Holder shall pay the sum of
$&#8195;&#8195;&#8195;&#8195;in immediately available funds to the Company in accordance with the terms of the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) Pursuant to this Exercise
Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(6) By its delivery of this
Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with
Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section&nbsp;11(a) of the Warrant to which this notice relates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name&nbsp;of&nbsp;Holder:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>d620082dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TYRA BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>T<SMALL>HIS</SMALL> S<SMALL>ECURITIES</SMALL> P<SMALL>URCHASE</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (the
&#147;<B><I>Agreement</I></B>&#148;) is made as of February&nbsp;1, 2024 (the&nbsp;&#147;<B><I>Effective Date</I></B>&#148;), by and between <B>T<SMALL>YRA</SMALL> B<SMALL>IOSCIENCES</SMALL>, I<SMALL>NC</SMALL>.</B>, a Delaware corporation (the
&#147;<B><I>Company</I></B>&#148;), and each of the purchasers whose names and addresses are set forth on <U>Schedule A</U> hereto (each, a &#147;<B><I>Purchaser</I></B>&#148; and, collectively, the &#147;<B><I>Purchasers</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, the Purchasers desire to purchase, severally and not jointly, and the Company
has agreed to sell, (i)&nbsp;shares (the &#147;<B><I>Shares</I></B>&#148;) of the Company&#146;s common stock, par value $0.0001 per share (the &#147;<B><I>Common Stock</I></B>&#148;), and <FONT STYLE="white-space:nowrap">(ii)&nbsp;pre-funded</FONT>
warrants, in the form attached hereto as <U>Exhibit A</U>, to purchase shares of Common Stock (each, a &#147;<B><I><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant</I></B>&#148; and collectively, the &#147;<B><I><FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</I></B>&#148;) (the shares of Common Stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the &#147;<B><I>Warrant Shares</I></B>&#148;). The Shares, <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Warrant Shares are collectively referred to herein as the &#147;<B><I>Securities</I></B>.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Company and the Purchasers hereby agree, severally and not jointly, as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION
1. AUTHORIZATION OF SALE OF SECURITIES. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has authorized the sale and issuance of the Securities to the
Purchasers on the terms and subject to the conditions set forth in this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 2. AGREEMENT TO SELL AND PURCHASE THE SECURITIES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.1 <B>Purchase</B>. At the Closing, the Company will issue, sell and deliver to each Purchaser, and such Purchaser will
purchase, severally and not jointly, from the Company, that number of Shares and, if elected by such Purchaser, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants set forth opposite such Purchaser&#146;s name on<U>&nbsp;Schedule
A</U>&nbsp;hereto, at a price per Share and, if applicable, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant equal to the Per Share Purchase Price and aggregate purchase price set forth thereon (the &#147;<B><I>Purchase
Price</I></B>&#148;). The election to receive <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants is solely at the option of the Purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.2 <B>Definitions</B>. For purposes of this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) &#147;<B><I>Affiliate</I></B>&#148; means, with respect to any Person, any Person that, directly or indirectly through one
or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) &#147;<B><I>Business Day</I></B>&#148; means a day, other than a Saturday or Sunday, on which banks in New York City are
open for the general transaction of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) &#147;<B><I>Common Stock Equivalents</I></B>&#148; shall mean any
securities of the Company that would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or
exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) &#147;<B><I>Exempt Issuance</I></B>&#148; means the issuance of
(a)&nbsp;shares of Common Stock, restricted stock units, options or other stock awards to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the <FONT
STYLE="white-space:nowrap">non-employee</FONT> members of the Board of Directors or a majority of the members of a committee of <FONT STYLE="white-space:nowrap">non-employee</FONT> directors established for such purpose for services rendered to the
Company, (b)&nbsp;the issuance and sale of the Securities to be issued hereunder and securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible
into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price,
exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, and (c)&nbsp;securities issued pursuant to any licensing, collaboration, acquisition or
strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating
company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is
issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities; provided, however, that the aggregate number of shares of Common Stock issued pursuant to clause (c)&nbsp;during the
restricted period shall not exceed 10% of the total number of shares of Common Stock issued and outstanding immediately following the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) &#147;<B><I>GAAP</I></B>&#148; means United States generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) &#147;<B><I>Governmental Entity</I></B>&#148; means any nation, federal, state, county, municipal, local or foreign
government, or other political subdivision thereof or any other governmental, administrative, judicial, arbitral, legislative, executive, regulatory or self-regulatory authority (including the Trading Market), instrumentality, agency, commission or
body and any entity exercising executive, legislative, judicial, regulatory, taxing or administrative functions of or pertaining to government. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) &#147;<B><I>Knowledge of the Company</I></B>&#148; shall mean, with respect to the Company, the knowledge, following due
inquiry, of any of Todd Harris, Alan Fuhrman, Daniel Bensen, Hiroomi Tada, Ronald Swanson and Ali Fawaz. Such individuals will be deemed to have &#147;knowledge&#148; of a particular fact or other matter if such individual has or at any time had
actual knowledge of such fact or other matter or if, in the absence of such actual knowledge, such person reasonably should have known such fact or other matter based on their role in the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) &#147;<B><I>Law</I></B>&#148; means any federal, state, local or foreign law (including common law), statute, code,
ordinance, rule, regulation, order, judgment, writ, stipulation, award, injunction, decree, arbitration award or finding or any other legally enforceable requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) &#147;<B><I>Material Adverse Effect</I></B>&#148; means any change, event, development, condition, occurrence or effect
that, individually or in the aggregate with all other changes, events, developments, conditions, occurrences or effects (a)&nbsp;is, or could reasonably be expected to be, materially adverse to the business, financial condition, prospects, assets,
liabilities or results of operations of the Company and its subsidiaries considered as one enterprise, or (b)&nbsp;materially impairs the ability of the Company to comply, or prevents the Company from complying, with its material obligations with
respect to the Closing or would reasonably be expected to do so, or (c)&nbsp;is, or could reasonably be expected to be, materially adverse to the validity of the Securities purchased hereunder or the legal authority of the Company to comply in all
material respects with the terms of this Agreement;<U>&nbsp;provided</U>,<U>&nbsp;however</U>, that none of the following will be deemed in themselves, either alone or in combination, to constitute, and that none of the following will be taken into
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
account in determining whether there has been or will be, a Material Adverse Effect under subclause (a)&nbsp;of this definition: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">any change generally affecting the economy, financial markets or political, economic or regulatory
conditions in the United States or any other geographic region in which the Company conducts business, if the Company is not disproportionately affected thereby; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">general financial, credit or capital market conditions, including interest rates or exchange rates, or any
changes therein, if the Company is not disproportionately affected thereby; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">any change that generally affects industries in which the Company conducts business, if the Company is not
disproportionately affected thereby; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">changes in Laws after the date hereof, if the Company is not disproportionately affected thereby;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">v.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">changes in GAAP after the date of this Agreement, if the Company is not disproportionately affected thereby;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">vi.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">any change arising in connection with earthquakes, hostilities, acts of war, sabotage or terrorism or
military actions or any escalation or material worsening of any such hostilities, acts of war, sabotage or terrorism or military actions; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided, that the underlying cause of any change described in the foregoing clauses (i) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">through (vi)&nbsp;may be deemed to constitute, or be taken into account in determining whether there has been or will be, a Material Adverse
Effect under subclause (a)&nbsp;of this definition, except to the extent any such change would otherwise be excepted from this definition in accordance with the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j) &#147;<B><I>Per Share Purchase Price</I></B>&#148; equals $13.01, subject to adjustment for reverse and forward stock
splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement and prior to the Closing, provided that the purchase price per
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant shall be the Per Share Purchase Price minus $0.001. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(k)
&#147;<B><I>Person</I></B>&#148; means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental
authority or any other form of entity not specifically listed herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(l) &#147;<B><I>subsidiary</I></B>&#148; means any
individual or entity the Company wholly-owns or controls, or in which the Company, directly or indirectly, owns a majority of the voting stock or similar voting interest, in each case that would be disclosable pursuant to Item 601(b)(21) of
Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated under the Securities Act (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(m)
&#147;<B><I>Trading Day</I></B>&#148; means a day on which the Trading Market is open for trading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(n)
&#147;<B><I>Trading Market</I></B>&#148; means the Nasdaq Global Select Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All references herein to &#147;subsidiaries&#148; or
&#147;a subsidiary&#148; of the Company (other than the references appearing in this <U>Section</U><U></U><U>&nbsp;2.2</U>, <U>Section</U><U></U><U>&nbsp;4.1</U> and <U>Section</U><U></U><U>&nbsp;8.9</U>) shall be disregarded, <U>mutatis
mutandis</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 3. CLOSING, CLOSING CONDITIONS AND CLOSING DELIVERIES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.1 <B>Closing</B>. The closing of the purchase and sale of the Securities pursuant to this Agreement (the
&#147;<B><I>Closing</I></B>&#148;) shall occur on February&nbsp;6, 2024, subject to the satisfaction or waiver of all of the conditions set forth in<U>&nbsp;Section</U><U></U><U>&nbsp;3.2</U>&nbsp;and the delivery of all of the closing deliveries
set forth in<U>&nbsp;Section</U><U></U><U>&nbsp;3.3</U>&nbsp;(such date, the &#147;<B><I>Closing Date</I></B>&#148;), at the offices of Latham&nbsp;&amp; Watkins LLP, 12670 High Bluff Drive, San Diego, CA, 92130, or at such other time and place as
may be agreed to by the Company and the Purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.2 <B>Closing Conditions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Mutual Closing Condition</U>. There shall have been no Law enacted, entered, promulgated, enforced or deemed applicable
by any Governmental Entity of competent jurisdiction that is in effect and makes illegal or otherwise prohibits or materially delays the consummation of the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Conditions to Purchaser&#146;s Obligations</U>. Each Purchaser&#146;s obligation to purchase the Securities at the
Closing is subject to the fulfillment, on or before the Closing, of each of the following conditions, unless waived: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company&#146;s representations and warranties in<U>&nbsp;Section</U><U></U><U>&nbsp;4</U>&nbsp;shall be
true and correct in all material respects at the date of the Closing (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects), with the same force and effect as if they had been made
on and as of said date, other than the representations and warranties set forth in Sections 4.1, 4.2, 4.3, 4.5, 4.8, 4.9, and 4.14 which shall be true and correct in all respects as if they had been made on and as of said date.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company shall have performed and complied with in all material respects all agreements and conditions
herein required to be performed or complied with by the Company on or before the Closing, or any breach or failure to do so has been cured. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">There shall have been no Material Adverse Effect with respect to the Company since the date hereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">From the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the
Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) or the Trading Market, nor shall suspension have been threatened either (A)&nbsp;in writing by the Commission or the Trading Market or (B)&nbsp;by falling below the
minimum maintenance requirements of the Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been
established on securities whose trades are reported by such service, or on the Trading Market, nor shall a banking moratorium have been declared by the United States, New York State or California authorities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">v.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company shall have filed with the Trading Market a Listing of Additional Shares notification form for
the listing of the Shares and the Warrant Shares. No objection shall have been raised by the Trading Market with respect to the consummation of the transactions contemplated by this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">vi.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company shall have delivered the closing deliverables set forth in <U>Section</U><U></U><U>&nbsp;3.3</U>
to the Purchasers. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">vi.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company shall have obtained any and all consents, permits, approvals, registrations and waivers
necessary for the consummation of the purchase and sale of the Securities and the consummation of the other transactions contemplated by this Agreement, including the waiver of any applicable registration rights that could affect the rights of the
Purchasers hereunder, all of which shall be in full force and effect. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U>Conditions to the
Company&#146;s Obligations</U>. The Company&#146;s obligation to issue and sell the Securities at the Closing to a Purchaser is subject to the fulfillment, on or before the Closing, of each of the following conditions, unless waived: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Such Purchaser&#146;s representations and warranties in<U>&nbsp;Section</U><U></U><U>&nbsp;5</U>&nbsp;shall
be true and correct in all material respects at the date of the Closing, with the same force and effect as if they had been made on and as of said date, except to the extent any such representation or warranty expressly speaks as of an earlier date,
in which case such representation or warranty shall be true and correct in all material respects as of such earlier date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Such Purchaser shall have performed and complied with in all material respects all agreements and conditions
herein required to be performed or complied with by it on or before the Closing, or any breach or failure to do so has been cured. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.3 <B>Closing Deliveries.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <B>Payment of the Purchase Price at Closing</B>. At the Closing, each Purchaser shall deliver, or cause to be delivered,
to the Company, an amount equal to such Purchaser&#146;s aggregate Purchase Price as set forth on <U>Schedule A </U>hereto by wire transfer of immediately available funds to the Company&#146;s account pursuant to wire instructions set forth in
<U>Schedule B</U>. Each Purchaser&#146;s obligations to pay the Purchase Price shall be several and not joint. If a Purchaser informs the Company (i)&nbsp;that it is an investment company registered under the Investment Company Act of 1940, as
amended, (ii)&nbsp;that it is advised by an investment adviser subject to regulation under the Investment Advisers Act of 1940, as amended, or (iii)&nbsp;that its internal compliance policies and procedures so require it, then (1)&nbsp;prior to the
delivery by such Purchaser of its Purchase Price, the Company shall deliver evidence of the issuance of the Shares from the Company&#146;s transfer agent as described below in <U>Section</U><U></U><U>&nbsp;3.3(b)</U>, and (2)&nbsp;following receipt
of such evidence, such Purchaser shall deliver at the Closing its Purchase Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <B>Issuance of the Shares at the
Closing</B>. At the Closing, the Company shall issue, or cause the Company&#146;s transfer agent to issue, to each Purchaser in global form through a book-entry account maintained by the Company&#146;s transfer agent the number of Shares purchased
by such Purchaser, as set forth in<U>&nbsp;Schedule A</U>&nbsp;hereto, at the Closing against payment by such Purchaser of the Purchase Price (including providing a copy of the irrevocable instructions delivered by the Company to the Company&#146;s
transfer agent instructing the transfer agent to issue such Shares to the Purchaser (or its nominee in accordance with such Purchaser&#146;s delivery instructions) by crediting such Shares to the Purchaser&#146;s account (or the account of its
nominee in accordance with such Purchaser&#146;s delivery instructions) on the transfer agent&#146;s book-entry system on the Closing Date and confirmation from the transfer agent that such Shares were so issued on the date thereof, or if required
by such Purchaser, a copy of the book-entry statement reflecting the issuance of such Shares). Such Shares shall be appropriately legended as set forth in<U>&nbsp;Section</U><U></U><U>&nbsp;5.11</U>&nbsp;herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <B>Issuance of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT></B> <B>Warrants at the Closing</B>. At the Closing,
if applicable for such Purchaser, the Company will deliver or cause to be delivered to each such Purchaser (or such Purchaser&#146;s designated custodian per its delivery instructions) a PDF copy of the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant purchased by such Purchaser (with the original <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to be delivered to Purchaser within
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
five (5)&nbsp;Business Days of Closing), registered in such Purchaser&#146;s name. Such delivery shall be against payment of the Purchase Price therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <B>Secretary&#146;s Certificate</B>. At the Closing, the Purchasers shall have received a certificate signed by the
Secretary of the Company, in form and substance reasonably satisfactory to the Purchasers, (i)&nbsp;certifying the resolutions of the Board of Directors of the Company or a duly authorized committee thereof approving this Agreement and all of the
transactions contemplated hereunder, (ii)&nbsp;certifying the current versions of the Company&#146;s Certificate of Incorporation and Bylaws and (iii)&nbsp;attaching a certificate evidencing the good standing of the Company in Delaware issued by the
Secretary of State of Delaware, as of a date within five Business Days of the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) <B>Compliance
Certificate</B>. At the Closing, the Purchasers shall have received a certificate, in form and substance reasonably satisfactory to the Purchasers, signed by the President and Chief Executive Officer of the Company certifying to the fulfillment of
the conditions set forth in<U>&nbsp;Section</U><U></U><U>&nbsp;3.2(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) <B>Opinion. </B>At the Closing, the
Purchasers shall have received an opinion of Latham&nbsp;&amp; Watkins LLP, counsel for the Company, dated as of the Closing Date, in a form reasonably satisfactory to the Purchasers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) <B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</B>. At the Closing, the Purchasers shall have received
executed <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, dated as of the date hereof, by and among the Company and the directors and executive officers of the Company, all of whom are listed on <U>Schedule C</U> hereto, in the form
attached hereto as <U>Exhibit B</U> (the &#147;<B><I>D&amp;O <FONT STYLE="white-space:nowrap">Lock-up</FONT></I></B>&#148;), which <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement may only be waived by the Company upon receipt of written
consent of the Purchasers holding at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the Securities issued hereunder and then-held by all Purchasers (the &#147;<B><I>Requisite Purchasers</I></B>&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 4. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except as disclosed in the SEC Documents (as defined below) that have been filed at least one (1)&nbsp;Business Day prior to
the Effective Date and only as and to the extent disclosed therein, the Company hereby represents, warrants and covenants to the Purchasers as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.1 <B>Organization and Standing; Subsidiaries</B>. The Company has been duly incorporated or organized and is validly
existing and in good standing under the laws of Delaware or other jurisdiction of incorporation or organization, has full corporate or other power and authority necessary to own or lease its properties and conduct its business as presently
conducted, and is duly qualified as a foreign corporation and in good standing in all jurisdictions in which the character of the property owned or leased or the nature of the business transacted by it makes qualification necessary, except where the
failure to be so qualified would not have a Material Adverse Effect. The Company owns, directly or through subsidiaries, all of the issued outstanding equity securities of each of its subsidiaries. Each of the Company&#146;s subsidiaries has been
duly incorporated or organized and is validly existing and in good standing under the laws of its jurisdiction of incorporation or organization, has full corporate or other power and authority necessary to own or lease its properties and conduct its
business as presently conducted, and is duly qualified as a foreign corporation and in good standing in all jurisdictions in which the character of the property owned or leased or the nature of the business transacted by it makes qualification
necessary, except where the failure to be so qualified would not have a Material Adverse Effect. The Company has no subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.2 <B>Corporate Power; Authorization</B>. The Company has all requisite corporate power and authority, and the Company and
its Board of Directors have taken all requisite corporate action, to authorize, execute and deliver this Agreement and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, to consummate the transactions contemplated herein and therein,
including to sell, issue and deliver the Securities to the Purchasers, and to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
carry out and perform all of the Company&#146;s obligations hereunder and thereunder. This Agreement has been duly authorized, executed and delivered by the Company and constitutes the legal,
valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except (i)&nbsp;as limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the
enforcement of creditors&#146; rights generally and (ii)&nbsp;as limited by equitable principles generally, including any specific performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.3 <B>Issuance and Delivery of the Securities</B>. The Shares have been duly authorized and, when issued and paid for in
compliance with the provisions of this Agreement, will be validly issued, fully paid and nonassessable. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants have been duly authorized by the Company and when executed and delivered by the
Company will be valid and binding agreements of the Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws
relating to or affecting the rights and remedies of creditors or by general equitable principles. The issuance and delivery of the Shares or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants is not subject to
<FONT STYLE="white-space:nowrap">preemptive,&nbsp;co-sale,&nbsp;right</FONT> of first refusal or any other similar rights of the stockholders of the Company or any other Person or any liens, encumbrances or restrictions, other than encumbrances
under applicable securities laws. The Warrant Shares have been duly authorized and reserved for issuance and, when issued and delivered upon valid exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in accordance therewith,
will be validly issued, fully paid and nonassessable, and not subject to <FONT STYLE="white-space:nowrap">preemptive,&nbsp;co-sale,&nbsp;right</FONT> of first refusal or any other similar rights of the stockholders of the Company or any other Person
or any liens, encumbrances or restrictions, other than encumbrances under applicable securities laws or the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. Assuming the accuracy of the representations made by the Purchasers
in<U>&nbsp;Section</U><U></U><U>&nbsp;5</U>, the offer and issuance by the Company of the Securities is exempt from registration under the Securities Act of 1933, as amended (the &#147;<B><I>Securities Act</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.4 <B>SEC Documents; Financial Statements; Independent Accountants</B>. The Company is not an &#147;ineligible issuer&#148;
(as defined in Rule 405 promulgated under the Securities Act). The Company is subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the &#147;<B><I>Exchange Act</I></B>&#148;), and has filed or furnished or will
file or furnish in a timely manner all reports, schedules, forms, statements and other documents that the Company was or is required to file with the Commission under either the Securities Act or the Exchange Act, for the one year preceding the date
hereof (the foregoing documents (together with any documents filed by the Company under the Securities Act or Exchange Act, whether or not required), and in each case including all exhibits and schedules thereto and documents incorporated by
reference therein and including all registration statements and prospectuses filed with the Commission, but excluding any information for which the Company has received confidential treatment from the Commission, being collectively referred to
herein as the &#147;<B><I>SEC Documents</I></B>&#148;). As of their respective filing or furnishing dates (or, if amended prior to the date of this Agreement, when amended), all SEC Documents (including any audited or unaudited financial statements
and any notes thereto or schedules included therein) complied in all material respects with the requirements of the Securities Act or the Exchange Act, as the case may be, and the rules and regulations of the Commission promulgated thereunder. None
of the SEC Documents as of their respective filing or furnishing dates contained any untrue statement of material fact or omitted to state a material fact required to be stated therein or necessary to make the statements made therein, in light of
the circumstances under which they were made, not misleading. There are no material outstanding or unresolved comments in comment letters from the staff of the Division of Corporation Finance of the Commission with respect to any SEC Documents. The
Company meets the requirements for the use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act. The financial statements (including the notes thereto) of the Company set forth in the SEC Documents (the &#147;<B><I>Financial
Statements</I></B>&#148;) comply in all material respects with applicable accounting requirements and with the published rules and regulations of the Commission with respect thereto. The Financial Statements have been prepared in accordance with
GAAP consistently applied during the periods involved and fairly present the financial position of the Company at the dates thereof and the results of its operations and cash flows for the periods then ended
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
(subject, in the case of unaudited statements, to normal, immaterial recurring adjustments). Except as set forth in the Financial Statements filed prior to the date hereof, the Company has not
incurred any liabilities, contingent or otherwise, except those incurred in the ordinary course of business, consistent (as to amount and nature) with past practices since the date of such Financial Statements, none of which, individually or in the
aggregate, have had or would reasonably be expected to have a Material Adverse Effect. The accountants who certified the Financial Statements are independent public accountants as required by the Securities Act and the Exchange Act and the
regulations thereunder and the Public Company Accounting Oversight Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.5 <B>Capitalization</B>. The authorized
capital stock of the Company consists of 500,000,000 shares of Common Stock and 50,000,000 shares of preferred stock. As set forth in the SEC Documents as of the date set forth therein, all of the Company&#146;s outstanding shares of capital stock
have been duly authorized and validly issued and are fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and were not issued in violation of or subject to any preemptive right or other rights to
subscribe for or purchase securities. Except as disclosed in the SEC Documents, there are no existing options, warrants, calls, subscriptions or other rights, agreements, arrangements or commitments of any character, relating to the issued or
unissued capital stock of the Company, obligating the Company to issue, transfer, sell, redeem, purchase, repurchase or otherwise acquire or cause to be issued, transferred, sold, redeemed, purchased, repurchased or otherwise acquired any capital
stock or voting debt of, or other equity interest in, the Company or securities or rights convertible into or exchangeable for such shares or equity interests or obligations of the Company to grant, extend or enter into any such option, warrant,
call, subscription or other right, agreement, arrangement or commitment.&nbsp;Neither the execution of this Agreement nor the issuance of Common Stock or other securities pursuant to any provision of this Agreement or the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants will give rise to any preemptive rights or rights of first refusal on behalf of any Person or result in the triggering of any anti-dilution or other similar rights (including a rights
distribution under any &#147;poison pill&#148; plan or similar arrangement). Other than the Common Stock, there are no other shares of any other class or series of capital stock of the Company issued or outstanding. The Company&#146;s Certificate of
Incorporation, as amended and as in effect on the date hereof (the &#147;<B><I>Certificate of Incorporation</I></B>&#148;), and the Company&#146;s Bylaws, as amended and as in effect on the date hereof (the &#147;<B><I>Bylaws</I></B>&#148;), are
included in the SEC Documents, and the Company shall not amend or otherwise modify the Certificate of Incorporation or Bylaws prior to the Closing. Except as disclosed in the SEC Documents, there are no voting agreements, <FONT
STYLE="white-space:nowrap">buy-sell</FONT> agreements, option or right of first purchase agreements or other agreements of any kind among the Company and any of the security holders of the Company relating to the securities of the Company held by
them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.6 <B>Litigation</B>. There are no legal, governmental or regulatory actions, suits, investigations, charges,
claims, complaints, audits, inquiries or other proceedings pending or, to the Knowledge of the Company, threatened against the Company or any of its subsidiaries, before or by any court, regulatory body or administrative agency or any other
governmental agency or body, domestic or foreign, which actions, suits or proceedings, individually or in the aggregate, could reasonably be expected to (a)&nbsp;challenge this Agreement or prohibit or delay the transactions contemplated herein or
(b)&nbsp;have a Material Adverse Effect, and to the Knowledge of the Company, there are no reasonable grounds for the same. Neither the Company nor any of its subsidiaries, is a party to or subject to the provisions of any injunction, judgment,
decree or order of any court, regulatory body, administrative agency or other governmental agency or body that might have a Material Adverse Effect. The Commission has not issued any stop order or other order suspending the effectiveness of any
registration statement filed by the Company under the Securities Act or the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.7 <B>Governmental
Consents</B>. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state, or local governmental authority or the Trading Market on the part of the Company is required
in connection with the consummation of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
transactions contemplated by this Agreement except for the filing of a Form D with the Commission under the Securities Act and compliance with the securities and blue sky laws in the states and
other jurisdictions in which shares of Common Stock are offered and/or sold, which compliance will be effected by the Company in accordance with such laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.8 <B>No Default or Consents</B>. Neither the Company nor any of its subsidiaries, is in violation or default under its
organizational documents. Neither the execution, delivery or performance of this Agreement or the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants by the Company nor the consummation of any of the transactions contemplated hereby or
thereby (including the issuance, sale and delivery by the Company of the Securities) will: (i)&nbsp;give rise to a right to terminate or accelerate the due date of any payment due under, or conflict with or result in the breach of any term or
provision of, or constitute a default (or an event which with notice or lapse of time or both would constitute a default) under, or require any consent or waiver under, or result in the execution or imposition of any lien, charge or encumbrance upon
any properties or assets of the Company or any subsidiary pursuant to the terms of, any indenture, mortgage, deed of trust or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which either or them or any
of their respective properties or businesses are bound, or any franchise, license, permit, judgment, decree, order, statute, rule or regulation (including federal and state securities laws and regulations) and the rules and regulations, assuming the
correctness of the representations and warranties made by the Purchasers herein, of any self-regulatory organization to which the Company or any of its subsidiaries or their securities are subject) applicable to the Company, or (ii)&nbsp;violate or
conflict with any provision of the Certificate of Incorporation or the Bylaws, except in the case of clause (i)&nbsp;as would not cause, either individually or in the aggregate, a Material Adverse Effect, and except for such consents or waivers
which have already been obtained and are in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.9 <B>No Material Adverse Change</B>. Since
September&nbsp;30, 2023, except as specifically disclosed in the SEC Documents, there have been no events, occurrences or developments that have had or would reasonably be expected to have, either individually or in the aggregate, a Material Adverse
Effect. Except for the transactions contemplated by this Agreement, no event, liability or development has occurred or exists with respect to the Company or any of its subsidiaries or their respective businesses, properties, operations or financial
conditions that would be required to be disclosed by the Company under applicable securities laws at the Effective Date that has not been publicly disclosed at least one Trading Day prior to the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.10 <B>No General Solicitation</B>. Neither the Company, nor any of its Affiliates, nor any Person acting on its or their
behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D promulgated under the Securities Act) in connection with the offer or sale of the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.11 <B>No Integrated Offering.</B>&nbsp;None of the Company or any of its Affiliates, or any Person acting on its or their
behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of any of the Securities under the Securities Act or cause this offering of
the Securities to be integrated with prior offerings by the Company for purposes of the Securities Act or any applicable stockholder approval provisions, including under the rules and regulations of the Trading Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.12 <B>Sarbanes-Oxley Act</B>. The Company is in material compliance with the requirements of the Sarbanes-Oxley Act of 2002
that are effective and applicable to the Company as of the date hereof, and the rules and regulations promulgated by the Commission thereunder that are effective and applicable to the Company as of the date hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.13 <B>Intellectual Property.</B><B></B>&nbsp;To the Knowledge of the
Company, the Company and its subsidiaries own, possess, license or have rights to use, on terms that the Company believes to be reasonable, all patents, patent applications, trademarks, trademark applications, service marks, trade names, copyrights,
licenses, trade <FONT STYLE="white-space:nowrap">secrets,&nbsp;know-how&nbsp;and</FONT> other similar rights that are necessary or material for use in connection with the businesses of the Company and its subsidiaries as described in the SEC
Documents (collectively, the &#147;<B><I>Intellectual Property Rights</I></B>&#148;).&nbsp;Neither the Company nor any of its subsidiaries has received a written notice that the Intellectual Property Rights used by the Company or any subsidiary
violates or infringes upon the rights of any Person.&nbsp;To the Knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The
Company and its subsidiaries have taken reasonable security measures to protect the secrecy and confidentiality of the Intellectual Property Rights (excluding any patents or patent applications that have or will become public), except where the
failure to do so would not, individually or in the aggregate, have a Material Adverse Effect. To the Knowledge of the Company, all material licenses or other material agreements under which the Company is granted rights to intellectual property, if
any, are in full force and effect and there is no material default by any other party thereto. The Company has no reason to believe that the licensors under such licenses and other agreements, if any, do not have and did not have all requisite power
and authority to grant the rights to the intellectual property purported to be granted thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.14
<B>Disclosure.</B>&nbsp;The Company understands and confirms that the Purchasers will rely on the representations, warranties and covenants set forth in this <U>Section</U><U></U><U>&nbsp;4</U> in effecting the transactions contemplated by this
Agreement. All due diligence materials regarding the Company and its business and the transactions contemplated hereby (including the information referred to in <U>Section</U><U></U><U>&nbsp;5.8</U> hereof), furnished by or on behalf of the Company
to the Purchasers upon their request are, when taken together with the SEC Documents, true and correct in all material respects and do not contain any untrue statement of material fact or omit to state a material fact necessary in order to make the
statements made therein, in light of the circumstances in which they were made, not misleading. The Company understands and agrees that each Purchaser, in making its decision to enter into this Agreement and purchase its Securities, will rely on
such due diligence materials and SEC Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.15 <B>Contracts.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Each indenture, contract, lease, mortgage, deed of trust, note agreement, loan or other agreement or instrument of a
character that is required to be described or summarized in the SEC Documents or to be filed as an exhibit to the SEC Documents under the Exchange Act and the rules and regulations promulgated thereunder (collectively, the &#147;<B><I>Material
Contracts</I></B>&#148;) is so described, summarized or filed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) The Material Contracts to which the Company or any of
its subsidiaries is a party have been duly and validly authorized, executed and delivered by the Company or such subsidiary and constitute the legal, valid and binding agreements of the Company or such subsidiary, enforceable by and against the
Company and its subsidiaries in accordance with their respective terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or other similar laws relating to enforcement of creditors&#146; rights
generally, and general equitable principles relating to the availability of remedies, except as rights to indemnity or contribution may be limited by federal or state securities laws. Neither the Company nor any of its subsidiaries nor, to the
Knowledge of the Company, any third party has violated any provision of, or failed to perform any obligation required under the provisions of, any of the Material Contracts. Neither the Company nor any of its subsidiaries nor, to the Knowledge of
the Company, any third party is in breach or default, or has received written notice of breach or default, of any of the Material Contracts. To the Knowledge of the Company, no event has occurred that, with notice or lapse of time or both, would
constitute such a breach or default pursuant to any Material Contract by the Company or any of its subsidiaries, or, to the Knowledge of the Company, any other party thereto, and, as of the date </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of this Agreement, neither the Company nor any of its subsidiaries has received written notice of the foregoing or from the counterparty to any Material Contract (or, to the Knowledge of the
Company, any of such counterparty&#146;s Affiliates) regarding an intent to terminate, cancel, or modify any Material Contract (whether as a result of a change of control or otherwise). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.16 <B>Properties and Assets.</B>&nbsp;The Company and its subsidiaries have good and marketable title to all the properties
and assets described as owned by them in the latest Financial Statements set forth in the SEC Documents, free and clear of all liens, mortgages, pledges or encumbrances of any kind except (a)&nbsp;those, if any, reflected in such Financial
Statements or (b)&nbsp;those that are not material in amount and do not adversely affect the use made and proposed to be made of such property by the Company or any subsidiary. The Company and its subsidiaries hold their respective leased properties
under valid and binding leases, except as would not have a Material Adverse Effect. The Company and its subsidiaries own or lease all such properties as are materially necessary to their respective operations as now conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.17 <B>Compliance and Regulatory</B>. The Company and its subsidiaries are in compliance with all applicable Laws of the
jurisdictions in which they are conducting their business, including all applicable local, state and federal environmental Laws (including Laws relating to the use, disposal or release of hazardous or toxic substances or relating to the protection
or restoration of the environment or human exposure to hazardous or toxic substances), and all applicable Laws enforced by the United States Food and Drug Administration (the &#147;<B><I>FDA</I></B>&#148;), (including the Federal Food, Drug And
Cosmetic Act, as amended, and the regulations promulgated thereunder) or any applicable laws enforced by equivalent Governmental Entities outside the United States, except where failures to be so in compliance, individually or in the aggregate,
would not reasonably be expected to have a Material Adverse Effect. Any preclinical tests and studies or clinical trials conducted by, on behalf of, or sponsored by the Company or any of its subsidiaries (&#147;<B><I>Studies</I></B>&#148;), were
and, if still pending, are being conducted in all material respects in accordance with all applicable laws and regulations and protocols governing the conduct of such Studies, the protocols, procedures and controls submitted to the FDA or any
foreign governmental body exercising comparable authority (together with the FDA, the &#147;<B><I>Regulatory Authorities</I></B>&#148;), and any conditions of approval and policies imposed by any institutional review board, ethics review board or
committee responsible for the oversight of such preclinical tests and studies and clinical trials. The descriptions of the Studies contained in the SEC Documents are accurate in all material respects; to the Knowledge of the Company, there are no
other preclinical studies and clinical trials, the results of which are inconsistent with or would call into question the results described in the SEC Documents in any material respect; and neither the Company nor any of its subsidiaries has
received any written notice or correspondence from the FDA or any other Regulatory Authority or institutional review board exercising comparable authority requiring or threatening the termination, suspension, or clinical hold of Studies, where such
termination, suspension or clinical hold would reasonably be expected to have a Material Adverse Effect, and to the Knowledge of the Company, there are no reasonable grounds for the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.18 <B>Taxes</B>. The Company and its subsidiaries have filed on a timely basis (giving effect to extensions) all required
federal, state and foreign income and franchise tax returns and have timely paid or accrued all taxes shown as due thereon, including interest and penalties, and, to the Knowledge of the Company, there is no tax deficiency that has been or might be
asserted or threatened against it or them that could have a Material Adverse Effect. All tax liabilities accrued through the date hereof have been adequately provided for on the books of the Company. There are no liens for material taxes upon the
assets of the Company or any of its subsidiaries other than for current taxes not yet due and payable or for taxes that are being contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP has been
made in the Company&#146;s most recent financial statements included in the SEC Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.19 <B>Investment Company.</B>&nbsp;The Company is not, and immediately
after receipt of payment for the Securities will not be, an &#147;investment company&#148; or an &#147;affiliated person&#148; of, or &#147;promoter&#148; or &#147;principal underwriter&#148; for an investment company, within the meaning of the
Investment Company Act of 1940, as amended, and the rules and regulations of the Commission promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.20
<B>Insurance.</B><B></B>&nbsp;The Company maintains insurance underwritten by insurers of recognized financial responsibility, of the types and in the amounts that the Company reasonably believes is adequate for the businesses of the Company and its
subsidiaries, including directors&#146; and officers&#146; liability insurance and insurance covering all real and personal property owned or leased by the Company or any of its subsidiaries against theft, damage, destruction, acts of vandalism and
all other risks customarily insured against and against such risks which the Company believes it is prudent to insure against, with such deductibles as are customary for companies in the same or similar business, all of which insurance is in full
force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.21 <B>Price of Common Stock.</B>&nbsp;The Company has not taken, and will not take, and no Person
acting on its behalf has taken or will take, directly or indirectly, any action designed to cause or result in, or that has constituted or that might reasonably be expected to constitute, the stabilization or manipulation of the price of any
security of the Company to facilitate the sale or resale of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.22 <B>Governmental Permits,
Etc.</B>&nbsp;The Company and its subsidiaries have all franchises, licenses, permits, certificates and other authorizations from such federal, state or local government or governmental agency, department or body that are currently necessary for the
operation of their respective businesses as currently conducted, including, without limitation, all such certificates, approvals, authorizations, exemptions, licenses and permits required by the FDA or any other comparable Governmental Entities,
including other Regulatory Authorities (collectively, &#147;<B><I>Permits</I></B>&#148;), except where the failure to possess such Permits would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Neither
the Company nor any of its subsidiaries has received any written notice requiring or threatening any revocation or modification of any such Permits, where such revocation or modification would reasonably be expected to have a Material Adverse
Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.23 <B>Internal Control over Financial Reporting; Disclosure Controls.</B>&nbsp;The Company maintains internal
control over financial reporting (as such term is defined in paragraph (f)&nbsp;of <FONT STYLE="white-space:nowrap">Rule&nbsp;13a-15&nbsp;under</FONT> the Exchange Act) as required by
<FONT STYLE="white-space:nowrap">Rule&nbsp;13a-15&nbsp;under</FONT> the Exchange Act. To the Knowledge of the Company, since the end of the Company&#146;s most recent audited fiscal year, there has been no material weakness in the design or
operation of the Company&#146;s internal control over financial reporting (whether or not remediated) which are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial information. The
Company&#146;s &#147;disclosure controls and procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> under the Exchange Act) are designed to provide reasonable assurance that all information (both financial and <FONT
STYLE="white-space:nowrap">non-financial)</FONT> required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules
and forms of the Commission, and that all such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.24 <B>Foreign Corrupt Practices.</B>&nbsp;Neither the Company nor any of its subsidiaries nor, to the Knowledge of the
Company, any director, officer, agent, employee or other Person acting on behalf of the Company or any of its subsidiaries, has, in the course of its actions for, or on behalf of, the Company or any subsidiary (a)&nbsp;used any corporate funds for
any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (b)&nbsp;made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds;
(c)&nbsp;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, the UK Bribery Act 2010 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
or any similar Law; or (d)&nbsp;made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.25 <B>Employee Relations.</B><B></B>&nbsp;No material labor dispute with the employees of the Company or any of its
subsidiaries, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company or any of its subsidiaries, exists or, to the Company&#146;s Knowledge, is threatened or imminent. No executive officer of the Company
(as defined in Rule 501(f) promulgated under the Securities Act) has notified the Company that such officer intends to leave the Company or otherwise terminate such officer&#146;s employment with the Company. To the Knowledge of the Company, no
executive officer of the Company is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information
<FONT STYLE="white-space:nowrap">agreement,&nbsp;non-competition&nbsp;agreement,</FONT> or any other agreement or any restrictive covenant involving or otherwise affecting such executive officer&#146;s relationship with the Company, and the
continued employment of each such executive officer does not subject the Company to any material liability with respect to any of the foregoing matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.26 <B>ERISA.</B>&nbsp;The Company and its subsidiaries are in compliance in all material respects with all presently
applicable provisions of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (&#147;<U>ERISA</U>&#148;); no &#147;reportable event&#148; (as defined in ERISA) has
occurred with respect to any &#147;pension plan&#148; (as defined in ERISA) for which the Company or any subsidiary would have any material liability; neither the Company nor any of its subsidiaries has not incurred or expects to incur material
liability under (a)&nbsp;Title IV of ERISA with respect to termination of, or withdrawal from, any &#147;pension plan&#148; or (b)&nbsp;Sections 412 or 4971 of the Internal Revenue Code of 1986, as amended, including the regulations and published
interpretations thereunder (the &#147;<B><I>Code</I></B>&#148;); and each &#147;Pension Plan&#148; for which the Company or any of its subsidiaries would have liability that is intended to be qualified under Section&nbsp;401(a)&nbsp;of the Code is
so qualified in all material respects and to the Knowledge of the Company, nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.27 <B>Registration Rights and Other Stockholder Agreements.</B><B></B>&nbsp;No Person has any right to cause the Company to
effect the registration under the Securities Act covering the transfer of any securities of the Company and there are no other stockholders agreements, voting agreements or other similar agreements with respect to the Company&#146;s capital stock to
which the Company is a party or, to the Company&#146;s Knowledge, between or among any of the Company&#146;s stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.28 <B>Trading Market Compliance.</B><B></B>&nbsp;The Company has not, in the previous twelve (12)&nbsp;months, received, nor
is there any reasonable basis for, (i)&nbsp;written notice from the Trading Market that the Company is not in compliance with the listing or maintenance requirements of the Trading Market that would result in immediate delisting or (ii)&nbsp;any
notification, Staff Delisting Determination, or Public Reprimand Letter (as such terms are defined in applicable listing rules of the Trading Market) that requires a public announcement by the Company of any noncompliance or deficiency with respect
to such listing or maintenance requirements. The Company is in compliance with all listing and maintenance requirements of the Trading Market on the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.29 <B>No &#147;Bad Actor&#148; Disqualification.</B>&nbsp;No &#147;bad actor&#148; disqualifying event described in Rule
506(d)(1)(i)-(viii) of the Securities Act (a &#147;<B><I>Disqualification Event</I></B>&#148;) is applicable to the Company or, to the Knowledge of the Company, any Company Covered Person (as defined below), except for a Disqualification Event to
which <FONT STYLE="white-space:nowrap">Rule&nbsp;506(d)(2)(ii-iv)&nbsp;or</FONT> (d)(3) is applicable. &#147;<B><I>Company Covered Person</I></B>&#148; means, with respect to the Company as an &#147;issuer&#148; for purposes of Rule 506 promulgated
under the Securities Act, any person listed in the first paragraph of Rule 506(d)(1). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.30 <B>OFAC. </B>None of the Company, any of its subsidiaries or, to the
Knowledge of the Company, any director, officer, agent, employee, Affiliate or representative of the Company or any of its subsidiaries is a Person that is, or is more than 50&nbsp;percent owned in the aggregate by or acting on behalf of one or more
Persons that are, currently the subject or target of any sanctions administered or enforced by the United States Government, including, without limitation, the U.S. Department of the Treasury&#146;s Office of Foreign Assets Control, the United
Nations Security Council, the European Union, His Majesty&#146;s Treasury, or other relevant sanctions authority (collectively, &#147;<B><I>Sanctions</I></B>&#148;), nor is the Company located, organized or resident in a country or territory that is
the subject of Sanctions; and the Company will not directly or indirectly use the proceeds of the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, to
fund any activities of or business (i)&nbsp;with any Person, or in any country or territory, that, at the time of such funding, is a designated target of Sanctions, (ii)&nbsp;in or involving a country or territory which at the time of such funding
is the subject of comprehensive country-wide or territory-wide Sanctions, or (iii)&nbsp;in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor,
investor or otherwise) of Sanctions. The Company has not knowingly engaged in, are not now knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or
transaction is or was the subject of Sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.31 <B>Shell Company Status.</B> The Company is not, and has never been,
an issuer identified in Rule 144(i)(1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.32 <B>Compliance with Anti-Money Laundering Laws</B>. The operations of the
Company and its subsidiaries are and have been conducted at all times in compliance in all material respects with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act
of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines
issued, administered or enforced by any governmental or regulatory agency (collectively, the &#147;<B><I>Anti-Money Laundering Laws</I></B>&#148;) and no action, suit or proceeding by or before any court or governmental or regulatory agency,
authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the Knowledge of the Company, threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.33 <B>No Additional Agreements.</B> The Company has no other agreements or understandings (including side letters) with any
Purchaser or any other Person to purchase Securities on terms more favorable to such Purchaser than as set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.34 <B>Transactions with Affiliates.</B> To the Knowledge of the Company, none of the officers or directors of the Company,
the Company&#146;s stockholders, the officers or directors of any stockholder of the Company, or any family member or affiliate of any of the foregoing, has either directly or indirectly any interest in, or is a party to, any transaction that would
be required to be disclosed as a related party transaction pursuant to Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.35 <B>Security.</B> Except as would not reasonably be expected to have a Material Adverse Effect, the Company and its
subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<B><I>IT Systems</I></B>&#148;) are adequate for, and operate and perform in
all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, and are free and clear of all material Trojan horses, time bombs, malware and other malicious code. Except
as would not reasonably be expected to have a Material Adverse Effect, the Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls designed to maintain and protect the
confidentiality, integrity, availability, privacy and security of all sensitive, confidential or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
regulated data (&#147;<B><I>Confidential Data</I></B>&#148;) used or maintained in connection with their businesses and Personal Data, and the integrity, availability continuous operation,
redundancy and security of all IT Systems. &#147;<B><I>Personal Data</I></B>&#148; means the following data used in connection with the Company&#146;s and its subsidiaries&#146; businesses and in their possession or control: (i)&nbsp;a natural
person&#146;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or other tax identification number, driver&#146;s license number, passport number, credit card number,
bank information, or customer or account number; (ii)&nbsp;information that identifies, relates to, or may reasonably be used to identify an individual; (iii)&nbsp;any information regarding an individual&#146;s medical history, mental or physical
condition, or medical treatment or diagnosis by a health care professional; (iv)&nbsp;an individual&#146;s health insurance policy number or subscriber identification number, any unique identifier used by a health insurer to identify the individual,
or any information in an individual&#146;s application and claims history; (v)&nbsp;any information which would qualify as &#147;protected health information&#148; under the Health Insurance Portability and Accountability Act of 1996, as amended by
the Health Information Technology for Economic and Clinical Health Act (collectively, &#147;<B><I>HIPAA</I></B>&#148;); (vi) any information which would qualify as &#147;personal data,&#148; &#147;personal information&#148; (or similar term) under
the Privacy Laws (as defined in <U>Section</U><U></U><U>&nbsp;4.36</U>); and (vii)&nbsp;any other piece of information that alone, or combined with other information, allows the identification of such natural person, or his or her family, or permits
the collection or analysis of any data related to an identified person&#146;s health or sexual orientation. To the Knowledge of the Company and except as would not reasonably be expected to have a Material Adverse Effect, during the past three
(3)&nbsp;years, there have been no breaches, outages or unauthorized uses of or accesses to the IT Systems, Confidential Data, and Personal Data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.36 <B>Compliance with Data Privacy Laws.</B> The Company and its subsidiaries are, and at all prior times were, in material
compliance with all applicable state and federal data privacy and security Laws and regulations regarding the collection, use, storage, retention, disclosure, transfer, disposal, or any other processing (collectively
&#147;<B><I>Process</I></B>&#148; or &#147;<B><I>Processing</I></B>&#148;) of Personal Data, including HIPAA, the California Consumer Privacy Act, and the European Union General Data Protection Regulation (EU 2016/679) (collectively, the
&#147;<B><I>Privacy Laws</I></B>&#148;). To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take all appropriate steps necessary to ensure compliance in all material respects with their
policies and procedures relating to data privacy and security, and the Processing of Personal Data and Confidential Data (the &#147;<B><I>Privacy Statements</I></B>&#148;). The Company and its subsidiaries have, except as would not reasonably be
expected, individually or in the aggregate, to have a Material Adverse Effect, at all times since January&nbsp;1, 2022 provided accurate notice of its Privacy Statements then in effect to its clients, employees, third party vendors and
representatives. None of such disclosures made or contained in any Privacy Statements have been materially inaccurate, misleading, incomplete, or in material violation of any Privacy Laws. The Company further represents that neither it nor any of
its subsidiaries: (i)&nbsp;has received notice of any actual or potential claim, complaint, proceeding, regulatory proceeding or liability under or relating to, or actual or potential violation of, any of the Privacy Laws, contracts related to the
Processing of Personal Data or Confidential Data, or Privacy Statements, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in
part, any investigation, remediation, or other corrective action pursuant to any Privacy Law or contract; or (iii)&nbsp;is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 5. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE PURCHASERS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each Purchaser, severally and not jointly, represents and warrants to and covenants with the Company that: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.1 <B>Risk.</B><B></B>&nbsp;Such Purchaser, taking into account the
personnel and resources it can practically bring to bear on the purchase of the Securities contemplated hereby, is knowledgeable, sophisticated and experienced in making, and is qualified to make, decisions with respect to investments in securities
presenting an investment decision like that involved in the purchase of the Securities, including investments in securities issued by the Company, and has requested, received, reviewed and considered all information such Purchaser deems relevant
(including the SEC Documents) in making an informed decision to purchase the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.2 <B>Purchase for
Investment.</B><B></B>&nbsp;Purchaser is acquiring the Securities pursuant to this Agreement for its own account for investment only and with no present intention of distributing any of such Securities or any arrangement or understanding with any
other Persons regarding the distribution of such Securities, except in compliance with <U>Section</U><U></U><U>&nbsp;5.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.3 <B>Reliance.</B>&nbsp;Such Purchaser understands that the Securities are being offered and sold to it in reliance upon
specific exemptions from the registration requirements of the Securities Act, the rules and regulations thereunder, and state securities laws and that the Company is relying upon the truth and accuracy of, and such Purchaser&#146;s compliance with,
the representations, warranties, agreements, acknowledgments and understandings of such Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of such Purchaser to acquire the Securities. If any of
the representations and warranties made by such Purchaser herein are no longer accurate in all material respects prior to Closing, such Purchaser shall promptly notify the Company. If such Purchaser is acquiring the Securities as a fiduciary or
agent for one or more investor accounts, it represents that it has sole investment discretion with respect to each such account and it has full power to make the foregoing representations, acknowledgements and agreements on behalf of such account.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.4 <B>Compliance with the Securities Act</B>. Such Purchaser will not, directly or indirectly, offer, sell, pledge,
transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the securities purchased hereunder except in compliance with the Securities Act, applicable blue sky laws, and the rules and
regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.5 <B>Accredited Investor.</B><B></B>&nbsp;Such Purchaser is an &#147;accredited
investor&#148; within the meaning of Rule&nbsp;501 of Regulation D promulgated under the Securities Act or a Qualified Institutional Buyer within the meaning of Rule 144A promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.6 <B>Power and Authority.</B><B></B>&nbsp;Such Purchaser has all requisite corporate power, and has taken all requisite
corporate action, to authorize, execute and deliver this Agreement and each of the other agreements and instruments contemplated herein to which the Purchaser is a party, to consummate the transactions contemplated herein and therein and to carry
out and perform all of such Purchaser&#146;s obligations hereunder and thereunder. Upon the execution and delivery of this Agreement, this Agreement shall constitute a valid and binding obligation of such Purchaser, enforceable in accordance with
its terms, except (i)&nbsp;as limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally and (ii)&nbsp;as limited by equitable principles
generally, including any specific performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.7 <B>Broker Dealer.</B>&nbsp;Such Purchaser is not a broker or dealer
registered pursuant to Section&nbsp;15 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.8 <B>Sophisticated Investor</B>. Such Purchaser
acknowledges that it is a sophisticated investor engaged in the business of assessing and assuming investment risks with respect to securities, including securities such as the Shares, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and
Warrant Shares, and further acknowledges that the Company is entering into this Agreement in reliance on this acknowledgment and such Purchaser&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
understanding, acknowledgment and agreement that the Purchaser may have agreed in writing with the Company to receive information regarding certain confidential matters as part of its due
diligence review that may represent material, <FONT STYLE="white-space:nowrap">non-public</FONT> information of the Company. Such Purchaser further acknowledges that it is aware of the restrictions imposed by United States securities laws on the
purchase or sale of securities by any Person who has received material, <FONT STYLE="white-space:nowrap">non-public</FONT> information from the issuer of such securities and on the communication of such information to any other Person when it is
reasonably foreseeable that such other Person is likely to purchase or sell such securities in reliance upon such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.9 <B>Other Securities Transactions.</B><B></B>&nbsp;Such Purchaser has not, either directly or indirectly through an
Affiliate, agent or representative of the Company, engaged in any transaction in the securities of the Company other than with respect to the transactions contemplated herein, since the time that the Purchaser was first contacted by the Company or a
representative of the Company regarding the transactions contemplated hereby until the date hereof, except as set forth in filings made with the Commission pursuant to the Exchange Act. Notwithstanding the foregoing, (a)&nbsp;in the case of a
Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#146;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by
the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement and (b)&nbsp;in the case of a Purchaser that is affiliated with other funds or investment vehicles or whose investment advisor or <FONT
STYLE="white-space:nowrap">sub-advisor</FONT> that routinely acts on behalf of or pursuant to an understanding with such Purchaser is also an investment advisor or <FONT STYLE="white-space:nowrap">sub-advisor</FONT> to other funds or investment
vehicles, the representation set forth above shall only apply with respect to the personnel of such other funds or investment vehicles or such investment advisor or <FONT STYLE="white-space:nowrap">sub-advisor</FONT> who had knowledge of the
transactions contemplated hereby and not with respect to any personnel who have been effectively walled off by appropriate information barriers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.10 <B>Independent Advice.</B><B></B>&nbsp;Such Purchaser understands that nothing in this Agreement or any other materials
presented to such Purchaser in connection with the purchase and sale of the Securities constitutes legal, tax or investment advice. Such Purchaser has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed
necessary or appropriate in connection with its purchase of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.11 <B>Legends.</B>&nbsp;Such Purchaser
understands that, until such time as the Securities may be sold pursuant to an effective registration statement or Rule 144 under the Securities Act (&#147;<B><I>Rule 144</I></B>&#148;) (or any other applicable exemption from the registration
requirements under the Securities Act), any certificates representing the Securities, whether maintained in a book entry system or otherwise, will bear one or more legends in substantially the following form and substance: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
&#147;SECURITIES ACT&#148;), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST
OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED, HYPOTHECATED OR OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO A TRANSACTION WHICH IS
EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS, AND, IN THE CASE OF A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, THE HOLDER WILL NOTIFY ANY SUBSEQUENT PURCHASER
OF THE SECURITIES EVIDENCED BY THIS CERTIFICATE FROM IT OF SUCH RESALE RESTRICTIONS.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, any stock certificates, whether maintained in a book entry
system or otherwise, representing the Securities may contain any legend required by the blue sky laws of any state to the extent such laws are applicable to the sale of such Securities hereunder. The Company shall promptly help facilitate the
removal of such legend as soon as it is legally permitted to do so under Rule 144, or to facilitate any transfer of the Securities under Rule 144 that may be requested by Purchasers, but shall not be obligated to incur any material, noncustomary
costs or expenses in taking such actions other than as set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.12 <B>Restricted Securities.</B>&nbsp;Such
Purchaser understands that the Securities are characterized as &#147;restricted securities&#148; under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under
such laws and applicable regulations such Securities may be resold without registration under the Securities Act only in certain limited circumstances. Accordingly, such Purchaser represents that it is familiar with Rule 144 of the Securities Act,
as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.13<B>
</B><B>Beneficial Ownership</B>. To each Purchaser&#146;s knowledge, the purchase by the Purchaser of the Securities issuable to it at the Closing will not result in the Purchaser (individually or together with any other Person with whom the
Purchaser has identified, or will have identified, itself as part of a &#147;group&#148; in a public filing made with the Commission involving the Company&#146;s securities, where such aggregation would be made according to Section&nbsp;13(d) of the
Exchange Act) acquiring, or obtaining the right to acquire, in excess of 19.999% of the outstanding shares of Common Stock or the voting power of the Company on a post-transaction basis that assumes that such Closing shall have occurred. The
Purchaser does not presently intend to, alone or together with others, make a public filing with the Commission to disclose that it has (or that it together with such other Persons have) acquired, or obtained the right to acquire, as a result of
such Closing (when added to any other securities of the Company that it or they then own or have the right to acquire), in excess of 19.999% of the outstanding shares of Common Stock or the voting power of the Company on a post-transaction basis
that assumes that each Closing shall have occurred (including assuming the effectiveness of any &#147;blocker&#148; or similar limitations on beneficial ownership contained in the applicable documentation for the Securities). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 6. REGISTRATION OF THE SECURITIES AND COMPLIANCE WITH THE SECURITIES ACT. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.1 <B>Registration Procedures and Expenses</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <B>Piggyback Rights</B>. In the event that the Company, in its sole discretion, shall determine to prepare and file a
registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3,&nbsp;or</FONT> any other appropriate form on which the Shares and Warrant Shares may be registered for resale (each of the Shares and Warrant Shares, together with any shares
of capital stock issued or issuable, from time to time, upon any reclassification, share combination, share subdivision, stock split, share dividend or similar transaction or event or otherwise as a distribution on, in exchange for or with respect
to any of the foregoing, in each case held at the relevant time by a Purchaser, the &#147;<B><I>Registrable Securities</I></B>&#148;) by the Purchasers, whether or not on a continuous basis pursuant to Rule 415 under the Securities Act, which such
registration statement may include shares that may be offered by the Company (the &#147;<B><I>Subsequent Registration Statement</I></B>&#148;), and has not previously filed a Secondary Registration Statement (as defined below), the Company shall:
(i)&nbsp;notify each Purchaser of such determination; and (ii)&nbsp;if, within ten (10)&nbsp;Business Days after receipt of such notice, any Purchaser requests in writing to include all or any part of its Registrable Securities in such Subsequent
Registration Statement, include the Registrable Securities as so requested by the applicable Purchaser. Notwithstanding the foregoing and for avoidance of doubt, the Company may, but shall not be required to, file a Subsequent Registration Statement
pursuant to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <B>Secondary Registration Statement.</B><B></B>&nbsp;The Company shall
prepare and file, on or before the date that is forty-five (45)&nbsp;days after the Closing (the &#147;<B><I>Filing Deadline</I></B>&#148;), with the Commission a Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT>
(except if the Company is not then eligible to register for resale the Registrable Securities on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> in which case such registration shall be on Form <FONT STYLE="white-space:nowrap">S-1)</FONT> (the
&#147;<B><I>Secondary Registration Statement</I></B>&#148;; where used hereafter, &#147;<B><I>Registration Statement</I></B>&#148; shall mean either a Subsequent Registration Statement which includes the Registrable Securities and permits their
resale on a continuous basis, or the Secondary Registration Statement, as applicable), relating to and providing for the resale of the Shares and Warrant Shares by the Purchasers on a continuous basis pursuant to Rule 415 under the Securities Act
or, if Rule 415 is not available for offers and sales of the Registrable Securities, by such other means of distribution of Registrable Securities as the Purchasers may reasonably specify. Notwithstanding the foregoing, if the Commission prevents
the Company from including any or all of the Registrable Securities on the Secondary Registration Statement due to limitations on the use of Rule 415 of the Securities Act for the resale of the Registrable Securities (and notwithstanding that the
Company used diligent efforts to advocate with the staff of the Commission for the registration of all or a greater portion of the Registrable Securities), the Secondary Registration Statement shall register for resale such number of Registrable
Securities that is equal to the maximum number of Registrable Securities as is permitted by the Commission. In such event, the number of Registrable Securities for which resale is to be registered for each selling shareholder named in the Secondary
Registration Statement shall be reduced pro rata among all such selling shareholders and as promptly as practicable after being permitted to register additional Registrable Securities under Rule 415 under the Securities Act, the Company amend the
Secondary Registration Statement or file one or more new registration statement(s) (such amendment or new registration statement, a &#147;<B><I>Remainder Registration Statement</I></B>&#148;) to register such additional Registrable Securities not
included in the Secondary Registration Statement and cause such Remainder Registration Statement to become effective as promptly as practicable after the filing thereof, but in any event no later than thirty (30)&nbsp;calendar days after the filing
of such Remainder Registration Statement (the &#147;<B><I>Remainder Effectiveness Deadline</I></B>&#148;); <I>provided</I>, that the Remainder Effectiveness shall be extended to sixty (60)&nbsp;calendar days after the filing of such Remainder
Registration Statement if the SEC notifies the Company that it will &#147;review&#148; such Remainder Registration Statement; <I>provided</I>, further, notwithstanding the foregoing, that the Company shall use reasonable best efforts to have such
Remainder Registration Statement declared effective within five (5)&nbsp;business days after the date the Company is notified orally or in writing (whichever is earlier) by the Commission that such Remainder Registration Statement will not be
reviewed or will not be subject to further review. Any failure by the Company to file the Secondary Registration Statement by the Filing Deadline or to effect the Secondary Registration Statement by the Effectiveness Deadline or the Remainder
Registration Statement by the Remainder Effectiveness Deadline shall not otherwise relieve the Company of its obligations to file or effect the Secondary Registration Statement or Remainder Registration Statement set forth in this
<U>Section</U><U></U><U>&nbsp;6.1(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) The Company shall use its reasonable best efforts, subject to receipt of
necessary information from the Purchasers, to cause the Commission to declare a Registration Statement covering the Shares and Warrant Shares effective as soon as practicable after the date of the filing thereof and in any event no later than the
earlier of (i)&nbsp;sixty (60)&nbsp;days after such filing if the Registration Statement has been filed on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3,&nbsp;and</FONT> no later than ninety (90)&nbsp;days after such filing if such Registration
Statement has been filed on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1,</FONT> and in either case, no later than forty-five (45)&nbsp;days after such filing in the event the Registration Statement is not reviewed by the Commission and
(ii)&nbsp;the fifth (5th) Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the Commission that the Registration Statement will not be reviewed or will not be subject to further review (in either
case, such date, the &#147;<B><I>Effectiveness Deadline</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) The Company shall promptly prepare and file
with the Commission such amendments and supplements to the Registration Statement and the prospectus used in connection therewith as may be necessary to keep the Registration Statement effective until the earliest of (i)&nbsp;such time as all of the
Shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and Warrant Shares purchased by the Purchasers pursuant to the terms of this Agreement have been sold pursuant to the Registration Statement, or (ii)&nbsp;such time as the Shares and Warrant
Shares become eligible for resale <FONT STYLE="white-space:nowrap">by&nbsp;non-Affiliates&nbsp;without</FONT> any volume limitations or other restrictions pursuant to Rule 144(b)(1)(i) or any other rule of similar effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) Notwithstanding the foregoing obligations, the Company may, upon written notice to the Purchasers, for a reasonable period
of time, not to exceed forty-five (45)&nbsp;days in the case of clauses (A)&nbsp;and (B)&nbsp;below, or thirty (30)&nbsp;days in the case of clause (C)&nbsp;below (each, a &#147;<B><I>Blackout Period</I></B>&#148;) and collectively not to exceed
seventy-five (75)&nbsp;days, delay a request for acceleration of the effective date, or suspend the effectiveness of any Registration Statement, in the event that (A)&nbsp;the Company is engaged in any activity or transaction or preparations or
negotiations for any activity or transaction that the Company desires to keep confidential for business reasons, if the Company&#146;s Board of Directors determines in good faith that the public disclosure requirements imposed on the Company under
the Securities Act in connection with the Registration Statement would require at that time disclosure of such activity, transaction, preparations or negotiations and such disclosure could result in material harm to the Company or its business
transactions or activities, (B)&nbsp;the Company does not yet have appropriate financial statements of any acquired or to be acquired entities necessary for filing, either because such financial statements are not yet available or despite the
Company using reasonable best efforts to procure such financial statements or (C)&nbsp;any other event occurs that makes any statement of a material fact made in such Registration Statement, including any document incorporated by reference therein,
untrue or that requires the making of any additions or changes in the Registration Statement in order to make the statements therein not misleading; provided, however, that in the case of a Blackout Period pursuant to clause (A)&nbsp;above, the
Blackout Period shall terminate upon the earlier of (i)&nbsp;such&nbsp;forty-five (45)&nbsp;day&nbsp;period or (ii)&nbsp;the completion, resolution or public announcement of the relevant transaction or event. If the Company suspends the
effectiveness of a Registration Statement pursuant to this <U>Section</U><U></U><U>&nbsp;6.1(e)</U>, the Company shall, as promptly as reasonably practicable following the termination of the circumstance which entitled the Company to do so, take
such actions as may be necessary to reinstate the effectiveness of such Registration Statement and give written notice to the Purchasers authorizing the Purchasers to resume offerings and sales pursuant to such Registration Statement. If as a result
thereof the prospectus included in such Registration Statement has been amended or supplemented to comply with the requirements of the Securities Act, the Company shall enclose such revised prospectus with the notice to each Purchaser given pursuant
to this <U>Section</U><U></U><U>&nbsp;6</U>. The Company shall be entitled to exercise its rights under this <U>Section</U><U></U><U>&nbsp;6.1(e)</U> not more than once in any six (6)&nbsp;month period; provided, however, that the aggregate number
of days of all Blackout Periods hereunder shall not exceed sixty (60)&nbsp;days in any twelve (12)&nbsp;month period. After the expiration of any Blackout Period and without further request from any Purchaser, the Company shall effect the filing (or
if required amendment or supplement) of the Registration Statement, or the filing of other documents, as necessary to allow the Purchasers to resell the Registrable Securities as set forth herein. In providing to a Purchaser the written notice of a
Blackout Period as contemplated by the first sentence of this Section&nbsp;6.1(e), the Company shall not (without the prior written consent of such Purchaser) disclose to such Purchaser any material nonpublic information giving rise to or otherwise
associated with such Blackout Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) Upon notification by the Commission that the Registration Statement will not be
reviewed or is not subject to further review by the Commission, the Company shall within three Business Days following the date of such notification request acceleration of such Registration Statement (with the requested effectiveness date to be not
more than two Business Days later). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) The Company shall furnish to the Purchasers with respect to the Shares and
Warrant Shares registered under any Registration Statement (and to each underwriter, if any, of such Shares and Warrant Shares) such number of copies of prospectuses and such other documents as the Purchaser may reasonably request, in order to
facilitate the public sale or other disposition of all or any of the Shares and/or Warrant Shares by the Purchaser. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) The Company shall bear all expenses in connection with the procedures in
paragraphs (a)&nbsp;through (g)&nbsp;of this <U>Section</U><U></U><U>&nbsp;6.1</U> and the registration of the Shares and Warrant Shares pursuant to the Registration Statement, other than fees and expenses, if any, of counsel or other advisers to
the Purchasers or underwriting discounts, brokerage fees and commissions incurred by the Purchaser, if any in connection with the offering of the Shares and Warrant Shares pursuant to the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) In order to enable the Purchasers to sell the Shares and Warrant Shares under Rule 144, the Company shall use its
reasonable best efforts to comply with the requirements of Rule 144, including without limitation, use its reasonable best efforts to comply with the requirements of Rule 144(c)(1) with respect to public information about the Company and to timely
file all reports required to be filed by the Company under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j) The Company shall provide the Purchasers
a reasonable opportunity to review and comment on all disclosures regarding the Purchasers and any plan of distribution proposed by them in connection with the preparation of any Registration Statement not less than five (5)&nbsp;Business Days prior
to the filing of such Registration Statement. Notwithstanding anything to the contrary contained herein, in no event shall the Company be permitted to name any Purchaser or Affiliate of a Purchaser as an &#147;underwriter&#148; without the prior
written consent of such Purchaser; <I>provided</I>, that if the Commission requires that a Purchaser be identified as a statutory underwriter in either the Secondary Registration Statement or a Remainder Registration Statement, such Purchaser will
have the option, in its sole and absolute discretion, to either (i)&nbsp;have the opportunity to withdraw from the Secondary Registration Statement or Remainder Registration Statement, as the case may be, upon its prompt written request to the
Company or (ii)&nbsp;be included as such in the Secondary Registration Statement or Remainder Registration Statement, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.2 <B>Restrictions on Transfer</B>. Each Purchaser agrees that it will not effect any disposition of the Securities that
would constitute a sale within the meaning of the Securities Act or pursuant to any applicable state securities laws, unless and until (1)&nbsp;there is then in effect a registration statement under the Securities Act covering such proposed
disposition and such disposition is made in accordance with such registration statement or (2)&nbsp;such disposition is otherwise permitted by law, including pursuant to the procedures set forth in Rule 144 or any other applicable exemption from the
registration requirements under the Securities Act. Notwithstanding the preceding sentence, no restriction shall apply to a transfer by a Purchaser that is (i)&nbsp;a partnership transferring to its partners or former partners in accordance with
partnership interests, or (ii)&nbsp;a limited liability company transferring to its members or former members in accordance with member interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.3 <B>Indemnification</B>. For the purpose of this <U>Section</U><U></U><U>&nbsp;6.3</U>: (i) the term
&#147;<B><I>Purchaser/Affiliate</I></B>&#148; shall mean any affiliate of the Purchaser, including, without limitation, any general partner or managing member of the Purchaser, any investment adviser of the Purchaser, or any transferee who is an
affiliate of the Purchaser, and any person who controls the Purchaser or any affiliate of the Purchaser within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act; and (ii)&nbsp;the term
&#147;<B><I>Registration Statement</I></B>&#148; shall include any preliminary prospectus, final prospectus (the &#147;<B><I>Prospectus</I></B>&#148;), free writing prospectus, exhibit, supplement or amendment included in or relating to, and any
document incorporated by reference in, the Registration Statement referred to in<U>&nbsp;Section</U><U></U><U>&nbsp;6.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) The Company agrees to indemnify and hold harmless the Purchasers and each Purchaser/Affiliate, against any losses, claims,
damages, liabilities or expenses, joint or several, that such Purchaser or Purchaser/Affiliate incurs, under the Securities Act, the Exchange Act, or any other federal or state statutory law or regulation, or at common law or otherwise (including in
settlement of any litigation, if such settlement is effected with the written consent of the Company, such consent not to be unreasonably withheld or delayed), insofar as such losses, claims, damages, liabilities or expenses (or actions in respect
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
thereof as contemplated below)&nbsp;(i) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact contained in the Registration Statement, including the
Prospectus, financial statements and schedules, and all other documents filed as a part thereof or incorporated by reference therein, as amended at the time of effectiveness of the Registration Statement, including any information deemed to be a
part thereof as of the time of effectiveness pursuant to paragraph (b)&nbsp;of Rule 430A under the Securities Act, or pursuant to Rules 430B, 430C or 434 under the Securities Act, or the Prospectus, in the form first filed with the Commission
pursuant to Rule 424(b) under the Securities Act, or filed as part of the Registration Statement at the time of effectiveness if no Rule 424(b) filing is required or any amendment or supplement thereto, or arise out of or are based upon the omission
or alleged omission to state in any of them a material fact required to be stated therein or necessary to make the statements in the Registration Statement or any amendment or supplement thereto not misleading or in the Prospectus or any amendment
or supplement thereto not misleading in light of the circumstances under which they were made, (ii)&nbsp;any violation or alleged violation by the Company or its agents of the Securities Act, the Exchange Act, or any other federal or state
securities law or any rule or regulation thereunder, in connection with the performance or <FONT STYLE="white-space:nowrap">non-performance</FONT> of its obligations under this Agreement or any action or inaction required of the Company in
connection with any registration or (iii)&nbsp;arise out of or are based in whole or in part on any inaccuracy in the representations or warranties of the Company contained in this Agreement, breach of any covenant of the Company contained in this
Agreement or any failure of the Company to perform its other obligations hereunder or under law, and will promptly reimburse each Purchaser and each Purchaser/Affiliate for any legal and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">other&nbsp;out-of-pocket&nbsp;expenses</FONT></FONT> as such expenses are reasonably incurred and documented by such Purchaser or such Purchaser/Affiliate in connection with investigating, defending or preparing to defend,
settling, compromising or paying any such loss, claim, damage, liability, expense or action; provided, however, that the Company will not be liable for amounts paid in settlement of any such loss, claim, damage, liability or action if such
settlement is effected without the written consent of the Company, which consent shall not be unreasonably withheld or delayed, and the Company will not be liable in any such case to the extent that any such loss, claim, damage, liability or expense
arises out of or is based upon (i)&nbsp;an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, the Prospectus or any amendment or supplement thereto in reliance upon and in conformity with
written information furnished to the Company by or on behalf of the Purchaser expressly for use therein, or (ii)&nbsp;the inaccuracy of any representation or warranty made by such Purchaser herein or (iii)&nbsp;any statement or omission in any
Prospectus that is corrected in any subsequent Prospectus that was delivered to the Purchaser prior to the pertinent sale or sales by the Purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Each Purchaser will severally, but not jointly, indemnify and hold harmless the Company, each of its directors, each of
its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, against any losses, claims, damages, liabilities
or expenses that the Company, each of its directors, each of its officers who signed the Registration Statement or controlling person reasonably incurs, under the Securities Act, the Exchange Act, or any other federal or state statutory law or
regulation, or at common law or otherwise (including in settlement of any litigation, but only if such settlement is effected with the written consent of such Purchaser, such consent not to be unreasonably withheld or delayed) insofar as such
losses, claims, damages, liabilities or expenses (or actions in respect thereof as contemplated below) arise out of or are based upon any untrue or alleged untrue statement of any material fact contained in the Registration Statement, the
Prospectus, or any amendment or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements in the Registration Statement
or any amendment or supplement thereto not misleading or in the Prospectus or any amendment or supplement thereto not misleading in the light of the circumstances under which they were made, in each case to the extent, but only to the extent, that
such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, the Prospectus, or any amendment or supplement thereto, in reliance upon and in conformity with written information furnished
to the Company by or on behalf of such Purchaser expressly for use </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
therein; and will reimburse the Company, each of its directors, each of its officers who signed the Registration Statement or controlling person for any legal and other expense reasonably
incurred by the Company, each of its directors, each of its officers who signed the Registration Statement or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability,
expense or action; provided, however, that (i)&nbsp;each Purchaser&#146;s aggregate liability under this <U>Section</U><U></U><U>&nbsp;6</U> shall not exceed the amount of net proceeds received by such Purchaser on the sale of the Registrable
Securities pursuant to the Registration Statement giving rise to such indemnification obligation, and (ii)&nbsp;a Purchaser will not be liable for amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is
effected without the written consent of such Purchaser, and (iii)&nbsp;a Purchaser will not be liable in any such case to the extent that any such loss, claim, damage, liability or expense arises out of or is based upon the gross negligence, fraud
or willful misconduct of the Company, any of Company&#146;s directors, any of Company&#146;s officers who signed the Registration Statement or any person who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or
Section&nbsp;20 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) Promptly after receipt by an indemnified party under this
<U>Section</U><U></U><U>&nbsp;6.3</U> of notice of the threat or commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this <U>Section</U><U></U><U>&nbsp;6.3</U>
promptly notify the indemnifying party in writing thereof, but the omission to notify the indemnifying party will not relieve it from any liability that it may have to any indemnified party for contribution or otherwise under the indemnity agreement
contained in this <U>Section</U><U></U><U>&nbsp;6.3</U> to the extent it is not prejudiced as a result of such failure. In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity
from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it may wish, jointly with all other indemnifying parties similarly notified, to assume the defense thereof with counsel reasonably
satisfactory to such indemnified party; provided, however, if the defendants in any such action include both the indemnified party, and the indemnifying party and the indemnified party shall have reasonably concluded, based on an opinion of counsel
reasonably satisfactory to the indemnifying party, that there may be a conflict of interest between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses
available to it and/or other indemnified parties that are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and
to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of its election to assume the defense of such action and approval by
the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this <U>Section</U><U></U><U>&nbsp;6.3</U> for any legal or other expenses subsequently incurred by such indemnified party in connection with
the defense thereof unless (i)&nbsp;the indemnified party shall have employed such counsel in connection with the assumption of legal defenses in accordance with the proviso to the preceding sentence (it being understood, however, that the
indemnifying party shall not be liable for the expenses of more than one separate counsel, reasonably satisfactory to such indemnifying party, representing all of the indemnified parties who are parties to such action) or (ii)&nbsp;the indemnifying
party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of action, in each of which cases the reasonable fees and expenses of
counsel shall be at the expense of the indemnifying party. In no event shall any indemnifying party be liable in respect of any amounts paid in settlement of any action unless the indemnifying party shall have approved in writing the terms of such
settlement; provided that such approval shall not be unreasonably withheld or delayed. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of or consent to the entry of any judgment in any
pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnification could have been sought hereunder by such indemnified party, unless such settlement or judgment (x)&nbsp;includes an
unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding, (y)&nbsp;imposes no liability or obligation on the indemnified person </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and (z)&nbsp;does not include any admission of fault, culpability, wrongdoing or malfeasance by or on behalf of the indemnified person. The indemnifying party shall notify the indemnified party
promptly of the institution, threat or assertion of any proceeding in connection with, arising out of, as a result of, relating to or based upon the transactions contemplated by this Agreement of which the indemnifying party is aware. Such indemnity
shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified party and shall survive the transfer of any of the Shares by any of the Purchasers as permitted by this Agreement. Subject to the terms of
this Agreement, all reasonable and documented fees and expenses of the indemnified party (including reasonable and documented fees and expenses to the extent incurred in connection with investigating or preparing to defend such proceeding in a
manner not inconsistent with this <U>Section</U><U></U><U>&nbsp;6.3</U>) shall be paid to such indemnified party, as incurred, within ten (10)&nbsp;Business Days of written notice thereof to the indemnifying party, provided that the indemnified
party shall promptly reimburse the indemnifying party for that portion of such fees and expenses applicable to such actions for which such indemnified party is finally judicially determined by a court of competent jurisdiction (which determination
is not subject to appeal or further review) not to be entitled to indemnification hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) If the indemnification
provided for in this <U>Section</U><U></U><U>&nbsp;6.3</U> is required by its terms but is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party under paragraphs (a), (b) or (c)&nbsp;of this
<U>Section</U><U></U><U>&nbsp;6.3</U> in respect to any losses, claims, damages, liabilities or expenses referred to herein, then each applicable indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result
of any losses, claims, damages, liabilities or expenses referred to herein (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company and the Purchaser from the private placement of Securities hereunder or
(ii)&nbsp;if the allocation provided by clause (i)&nbsp;above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;above but the relative fault of the
Company and the Purchaser in connection with the statements or omissions or inaccuracies in the representations and warranties in this Agreement and/or the Registration Statement that resulted in such losses, claims, damages, liabilities or
expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and each Purchaser on the other shall be deemed to be in the same proportion as the amount paid by such Purchaser to the
Company pursuant to this Agreement for the Securities purchased by such Purchaser that were sold pursuant to the Registration Statement bears to the difference (the &#147;<U>Difference</U>&#148;) between the amount such Purchaser paid for the
Securities that were sold pursuant to the Registration Statement and the amount received by such Purchaser from such sale. The relative fault of the Company on the one hand and each Purchaser on the other shall be determined by reference to, among
other things, whether the untrue or alleged statement of a material fact or the omission or alleged omission to state a material fact or the inaccurate or the alleged inaccurate representation and/or warranty relates to information supplied by the
Company or by such Purchaser and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The amount paid or payable by a party as a result of the losses, claims, damages,
liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in paragraph (c)&nbsp;of this <U>Section</U><U></U><U>&nbsp;6.3</U>, any legal or other fees or expenses reasonably incurred by such party in
connection with investigating or defending any action or claim. The provisions set forth in paragraph (c)&nbsp;of this <U>Section</U><U></U><U>&nbsp;6.3</U> with respect to the notice of the threat or commencement of any threat or action shall apply
if a claim for contribution is to be made under this paragraph (d); provided, however, that no additional notice shall be required with respect to any threat or action for which notice has been given under paragraph (c)&nbsp;for purposes of
indemnification. The Company and the Purchaser agree that it would not be just and equitable if contribution pursuant to this <U>Section</U><U></U><U>&nbsp;6.3</U> were determined solely by pro rata allocation (even if the Purchaser were treated as
one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this paragraph. Notwithstanding the provisions of this <U>Section</U><U></U><U>&nbsp;6.3</U>, (i) no
Purchaser shall be required to contribute any amount in excess of the amount by which the Difference exceeds the amount of any damages that such Purchaser has otherwise been required to pay by reason of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
such untrue or alleged untrue statement or omission or alleged omission and (ii)&nbsp;each Purchaser&#146;s aggregate liability under this <U>Section</U><U></U><U>&nbsp;6.3</U> shall not exceed
the amount of net proceeds received by such Purchaser on the sale of the Registrable Securities pursuant to the Registration Statement giving rise to such indemnification or contribution obligation. No person guilty of fraudulent misrepresentation
(within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Purchasers&#146; obligations to contribute pursuant to this
<U>Section</U><U></U><U>&nbsp;6.3</U> are several and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.4 <B>Information Available</B>. The Company, upon the
reasonable request of a Purchaser, shall make available for inspection by such Purchaser, any deemed underwriter participating in any disposition pursuant to the Registration Statement and any attorney, accountant or other agent retained by the
Purchasers or any deemed underwriter, all financial and other records, pertinent corporate documents and properties of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.5 <B>Delay in Filing or Effectiveness of Registration Statement</B>. If a Registration Statement covering the Shares and
Warrant Shares is not filed on or prior to the Filing Deadline or is not declared effective by the Commission on or prior to the Effectiveness Deadline, then for each day following the Filing Deadline or Effectiveness Deadline, as applicable, until
but excluding the date the Company files or the Commission declares effective the Registration Statement, as the case may be, the Company shall, for each such day, pay each Purchaser with respect to any such failure, as liquidated damages and not as
a penalty, an amount per&nbsp;thirty <FONT STYLE="white-space:nowrap">(30)-day&nbsp;period</FONT> equal to 1.0% of the purchase price paid by such Purchaser for its Shares and Warrant Shares pursuant to this Agreement (calculated on a daily pro rata
basis for any portion of such&nbsp;thirty <FONT STYLE="white-space:nowrap">(30)-day&nbsp;period</FONT> prior to the cure of such failure); and for any such&nbsp;thirty <FONT STYLE="white-space:nowrap">(30)-day&nbsp;period</FONT> (or earlier period
if such failure is cured prior to thirty (30)&nbsp;days), such payment shall be made no later than three (3)&nbsp;Business Days following such&nbsp;thirty <FONT STYLE="white-space:nowrap">(30)-day&nbsp;period</FONT> (or earlier period if such
failure is cured prior to thirty (30)&nbsp;days). Notwithstanding the foregoing provisions, in no event shall the Company be obligated to pay any liquidated damages pursuant to this <U>Section</U><U></U><U>&nbsp;6.5</U> to more than one Purchaser in
respect of the same Shares or Warrant Shares for the same period of time or in an aggregate amount that exceeds 6.0% of the purchase price paid by the Purchasers for the Shares and Warrant Shares pursuant to this Agreement. Such payments shall be
made to the Purchasers in cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 7. NO BROKER&#146;S FEE. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each of the Company and the Purchasers (on a several but not joint basis) hereby represents that no broker, investment banker,
financial advisor or other individual, corporation, general or limited partnership, limited liability company, firm, joint venture, association, enterprise, joint securities company, trust, unincorporated organization or other entity is entitled to
any broker&#146;s, finder&#146;s, financial advisor&#146;s or other similar fee or commission in connection with the transactions contemplated by this Agreement. The Company further agrees to indemnify each Purchaser for any claims, losses or
expenses incurred by such Purchaser as a result of the representation in this <U>Section</U><U></U><U>&nbsp;7</U> by the Company being untrue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION
8. COVENANTS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.1 <B>Form D; Blue Sky Filings</B>. The Company agrees to timely file a Form D with respect to the
Securities as required under Regulation D of the Securities Act. The Company will take such action as the Company shall reasonably determine is necessary in order to obtain an exemption from, or to qualify the Securities for, sale to the Purchasers
at the Closing pursuant to this Agreement under applicable securities or &#147;Blue Sky&#148; laws of the states of the United States, and shall provide evidence of such actions promptly upon the written request of any Purchaser. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.2 <B><FONT STYLE="white-space:nowrap">Lock-up</FONT></B>. The Company
covenants and agrees that it shall not waive the terms of any D&amp;O <FONT STYLE="white-space:nowrap">Lock-up</FONT> without the prior written consent of the Requisite Purchasers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.3 <B>Transfer Taxes.</B>&nbsp;On the Closing Date, all stock transfer or other taxes (other than income taxes) that are
required to be paid in connection with the issuance, sale and delivery of the Securities to the Purchasers hereunder will be fully paid or provided for by the Company and all laws imposing such taxes will have been fully complied with and the
Purchasers and their respective Affiliates shall have no obligation therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.4 <B>Listing of Common Stock</B>. The
Company shall promptly secure the listing of the Shares and Warrant Shares upon the Trading Market and each other national securities exchange and automated quotation system that requires an application by the Company for listing, if any, upon which
shares of Common Stock are then listed (subject to official notice of issuance) and shall maintain such listing, so long as any other shares of Common Stock shall be so listed. The Company shall use its reasonable best efforts to maintain the Common
Stock&#146;s listing on the Trading Market. The Company shall pay all fees and expenses in connection with satisfying its obligations under this <U>Section</U><U></U><U>&nbsp;8.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.5 <B>Reservation of Common Stock.</B> As of the date hereof, the Company has reserved and the Company shall continue to
reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue the Warrant Shares that are issuable upon the exercise of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.6 <B>Equal Treatment of Purchasers.</B> No consideration
(including any modification of documents related hereto) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of this Agreement or any documents related hereto unless the same consideration is also
offered to all Purchasers hereunder. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the
Purchasers as a class (subject to the proviso in the preceding sentence) and shall not in any way be construed as the Purchasers acting in concert or as a group (including a &#147;group&#148; within the meaning of Section&nbsp;13(d)(3) of the
Exchange Act) with respect to the purchase, disposition or voting of securities or otherwise. The Company does not have, and will not enter into, any agreement or understanding with any Purchaser that affords such Purchaser any rights or terms with
respect to the transactions contemplated by this Agreement (including the exhibits hereto) that are more beneficial to such Purchaser than those afforded to all other Purchasers hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.7 <B>Pledge of Securities</B>. The Company acknowledges and agrees that a Purchaser&#146;s Securities may be pledged by a
Purchaser in connection with a bona fide margin agreement or other loan or financing arrangement that is secured by the Securities. The pledge of Securities shall not be deemed to be a transfer, sale or assignment of the Shares hereunder, and no
Purchaser effecting a pledge of Securities shall be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement; provided that a Purchaser and its pledgee shall be required to
comply with the provisions of this Agreement in order to effect a sale, transfer or assignment of Shares to such pledgee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.8 <B>Adjustments in Share Numbers and Prices</B>. In the event of any stock split, subdivision, dividend or distribution
payable in shares of Common Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares of Common Stock), combination or other similar recapitalization or event occurring after the
date hereof and prior to the Closing, each reference this Agreement to a number of shares or a price per share shall be deemed to be amended to appropriately account for such event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.9 <B>Subsequent Equity Sales</B>. From the date hereof until the earlier
of (i)&nbsp;the date the Registration Statement is declared effective by the Commission, and (ii)&nbsp;sixty (60) days after the Closing Date, neither the Company nor any subsidiary shall issue, enter into any agreement to issue or announce the
issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents. Notwithstanding the foregoing, this <U>Section</U><U></U><U>&nbsp;8.9</U> shall not apply in respect of an Exempt Issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.10 <B>Legend Removal</B>. The Company shall, at its sole expense, upon appropriate notice from any Purchaser stating that
Registrable Securities have been sold pursuant to an effective Registration Statement, under Rule 144, or any other exemption from the registration requirements under the Securities Act, within two (2)&nbsp;Trading Days of such notice, cause its
transfer agent to timely prepare and deliver certificates or book-entry shares representing the Shares and Warrant Shares to be delivered to a transferee pursuant to such sale, which certificates or book-entry shares shall be free of any restrictive
legends and in such denominations and registered in such names as such Purchaser may request. Further, the Company shall, at its sole expense, cause its legal counsel or other counsel satisfactory to the transfer agent: (i)&nbsp;while the
Registration Statement is effective, to issue to the transfer agent a &#147;blanket&#148; legal opinion to allow sales without restriction pursuant to the effective Registration Statement, and (ii)&nbsp;provide all other opinions as may reasonably
be required by the transfer agent in connection with the removal of legends. A Purchaser may request that the Company remove, and the Company agrees to authorize the removal of, any legend from such Securities, following the delivery by a Purchaser
to the Company or the Company&#146;s transfer agent of either a legended certificate representing such Securities or, if the Securities are issued in book-entry form, a written request for legend removal: (i)&nbsp;following any sale of such
Securities pursuant to Rule 144 or any other applicable exemption from the registration requirements under the Securities Act, (ii)&nbsp;if such Securities are eligible for sale under Rule 144(b)(1), or (iii)&nbsp;following the time that the
Registration Statement is declared effective. If a legend removal request is made pursuant to the foregoing, the Company will, no later than two (2)&nbsp;Trading Days following the delivery by a Purchaser to the Company or the Company&#146;s
transfer agent of a legended certificate representing such Securities (or a request for legend removal, in the case of Securities issued in book-entry form), deliver or cause to be delivered to such Purchaser a certificate representing such
Securities that is free from all restrictive legends or an equivalent book-entry position, as requested by the Purchaser. Certificates for Securities free from all restrictive legends may be transmitted by the Company&#146;s transfer agent to a
Purchaser by crediting the account of the Purchaser&#146;s prime broker with the Depository Trust Company (&#147;<B><I>DTC</I></B>&#148;) as directed by such Purchaser. The Company warrants that the Securities shall otherwise be freely transferable
on the books and records of the Company as and to the extent provided in this Agreement. If a Purchaser effects a transfer of the Securities in accordance with <U>Section</U><U></U><U>&nbsp;5.11</U>, the Company shall permit the transfer and shall
promptly instruct its transfer agent to issue one or more certificates or credit shares to the applicable balance accounts at DTC in such name and in such denominations as specified by such Purchaser to effect such transfer. Each Purchaser hereby
agrees that the removal of the restrictive legend pursuant to this <U>Section</U><U></U><U>&nbsp;8.10</U> is predicated upon the Company&#146;s reliance that such Purchaser will sell any such Securities pursuant to either the registration
requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and such Purchaser shall deliver a certificate reasonably satisfactory to the Company to the foregoing effect. Prior to the
Company and its transfer agent agreeing to a form of representation letter to be given in connection with any legend removal opinion, the Company shall allow each Purchaser to review such form and shall cooperate, reasonably and in good faith, and
accept reasonable comments thereto from the Purchasers; and provided, further, that in no event shall the Purchaser be required to agree to indemnify, defend or hold harmless any Person.<B> </B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 9. NOTICES. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All
notices, requests, consents and other communications hereunder shall be in writing, shall be sent by confirmed facsimile or electronic mail, or mailed by first-class registered or certified airmail, or nationally recognized overnight express
courier, postage prepaid, and shall be deemed given when so sent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
in the case of facsimile or electronic mail transmission, or when so received in the case of mail or courier, and addressed as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if to the Company, to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Tyra Biosciences, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2656 State Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Carlsbad, CA 92008 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attn: Alan Fuhrman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Email: afuhrman@tyra.bio </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">with a copy to (which shall not constitute notice): </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ali Fawaz </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Email: afawaz@tyra.bio </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">with a copy to (which shall not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Latham&nbsp;&amp; Watkins LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12670 High Bluff Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">San Diego, CA 92130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attn:&nbsp;Matthew T. Bush </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Email: matt.bush@lw.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">or to such other Person at such other place as the Company shall designate to the Purchasers in writing; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) if to the Purchasers, to the applicable address set forth <U>Schedule A</U> or to such other Person at such other place as
the Purchasers shall designate to the Company in writing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 10. MISCELLANEOUS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.1 <B>Waivers and Amendments.</B>&nbsp;Neither this Agreement nor any provision hereof may be changed, waived, discharged,
terminated, modified or amended except upon the written consent of the Company and the Requisite Purchasers, in the case of any change, discharge, termination, modification, or of the party hereto against whom the waiver is to be effective, in the
case of a waiver, provided that (a)&nbsp;(i) prior to the Closing, the consent of the Requisite Purchasers shall include each Purchaser that, together with its affiliates and related funds, has subscribed to purchase Securities in the aggregate
amount of at least $18&nbsp;million, and (ii)&nbsp;following the Closing, the consent of the Requisite Purchasers shall include each Purchaser who, together with its affiliates and related funds, then holds Securities in the aggregate amount of at
least $18&nbsp;million, (b)&nbsp;if any amendment or waiver disproportionately and adversely affects a Purchaser (or a subset of Purchasers) in any material respect, the consent of such disproportionately affected Purchaser (or each Purchaser within
such subset of Purchasers) shall also be required and (c)&nbsp;the consent of each Purchaser shall be required for any change in the Purchase Price, any change in the type of security to be issued to Purchasers at Closing, or the amendment,
modification or waiver of this <U>Section</U><U></U><U>&nbsp;10.1</U>, of <U>Section</U><U></U><U>&nbsp;10.14</U> or of any of the closing conditions set forth in <U>Sections 3.2(b)(i)</U> or <U>3.2(b)(v)</U>. No waiver of any default with respect
to any provision, condition or requirement of this Agreement shall be deemed to be a continuing wavier in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or
omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. The failure of any party at any time to require another party&#146;s performance of any obligation under this Agreement shall not affect the
right subsequently to require performance of that obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.2 <B>Headings; Interpretation.</B>&nbsp;The headings of the various
sections of this Agreement have been inserted for convenience of reference only and shall not be deemed to be part of this Agreement. The terms &#147;hereof,&#148; &#147;herein,&#148; &#147;hereby&#148; and derivative or similar words refer to this
Agreement as a whole and not to any particular provision of this Agreement. Except when used together with the word &#147;either&#148; or otherwise for the purpose of identifying mutually exclusive alternatives, the term &#147;or&#148; has the
inclusive meaning represented by the phrase &#147;and/or.&#148; All references in this Agreement to &#147;dollars&#148; or &#147;$&#148; shall mean United States dollars. Except where the context otherwise requires, wherever used the singular shall
include the plural, the plural the singular, the use of any gender shall be applicable to all genders. The term &#147;including&#148; or &#147;includes&#148; means &#147;including without limitation&#148; or &#147;includes without limitation.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.3 <B>Severability.</B>&nbsp;In case any provision contained in this Agreement should be invalid, illegal or
unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.4 <B>Survival.</B>&nbsp;The representations and warranties contained herein shall survive the Closing and the delivery of
the Securities. The agreements and covenants contained herein shall survive for the applicable statute of limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.5 <B>Governing Law;</B><B></B><B>&nbsp;Jurisdiction.</B>&nbsp;This Agreement shall be governed by and interpreted in
accordance with the substantive laws of the State of New York, without regard to its or any other jurisdiction&#146;s choice of law rules. Any and all disputes arising out of, concerning, or related to this Agreement, or to the interpretation,
performance, breach or termination thereof shall be referred to and resolved by the federal courts located in New York, New York or, to the extent no such court does not have subject matter jurisdiction, the state courts of the State of New York
located in New York, New York (the &#147;<B><I>Specified Courts</I></B>&#148;). Each of the parties hereto irrevocably and unconditionally submits to the exclusive jurisdiction of the Specified Courts, waives any objection to the laying of venue of
any suit, action or proceeding brought in such courts and waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM
OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO
<FONT STYLE="white-space:nowrap">BE&nbsp;ALL-ENCOMPASSING&nbsp;OF</FONT> ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS
(INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY
FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.6 <B>Counterparts.</B>&nbsp;This Agreement may be executed in counterparts, each of which shall constitute an original, but
all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other party. Signatures to this Agreement transmitted by
facsimile, by email in &#147;portable document format&#148; (&#147;.pdf&#148;), or by any other electronic means intended to preserve the original graphic and pictorial appearance of this Agreement shall have the same effect as physical delivery of
the paper document bearing original signature. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.7 <B>Successors and Assigns.</B>&nbsp;Except as otherwise expressly
provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. None of the Purchasers may assign this Agreement or any rights or
obligations hereunder, in whole or in part, without the prior written consent of the Company, such consent not to be unreasonably withheld, conditioned or delayed; provided, however, that a Purchaser may assign its rights and delegate its duties
hereunder in whole or in part to an Affiliate or to a third party acquiring some or all of the Securities in a transaction complying with applicable securities laws without the prior written consent of the Company, provided such assignee agrees in
writing to be bound by the provisions hereof that apply to Purchasers. The Company may not assign this Agreement or any rights or obligations hereunder, in whole or in part, without the prior written consent of all Purchasers. Without limiting the
generality of the foregoing, in the event that the Company is a party to a merger, consolidation, share exchange or similar business combination transaction in which the Common Stock is converted into the equity securities of another Person, from
and after the effective time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term &#147;Company&#148; shall be deemed to refer to such Person and the term
&#147;Shares&#148;, <FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Warrants&#148;, or &#147;Warrant Shares&#148; shall be deemed to refer to the securities received by the Purchasers in exchange therefor in connection with such
transaction. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective permitted successors and assigns any rights, remedies, obligations, or liabilities under or by reason
of this Agreement, except as expressly provided in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.8 <B>No Third-Party Beneficiaries.</B>&nbsp;This
Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in
<U>Section</U><U></U><U>&nbsp;6.3</U> and this <U>Section</U><U></U><U>&nbsp;10.8</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.9 <B>Entire
Agreement.</B>&nbsp;This Agreement and the other documents and instruments delivered pursuant hereto or thereto, including the exhibits and schedules hereto or thereto, constitute the full and entire understanding and agreement between the parties
hereto with regard to the subjects hereof and thereof and supersede all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter hereof and thereof, <I>provided</I>, that any confidentiality
agreement that the Company and any Purchaser may have entered into in contemplation of potentially entering into this Agreement, shall survive in accordance with its terms and provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.10 <B>Independent Nature of Purchasers&#146; Obligations and Rights.</B>&nbsp;The obligations of each Purchaser under this
Agreement are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser under this Agreement. The decision of each Purchaser to
purchase Shares or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants pursuant to this Agreement has been made by such Purchaser independently of any other Purchaser. Nothing contained herein and no action taken by any Purchaser pursuant
thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group (within the meaning of
Section&nbsp;13(d) of the Exchange Act or otherwise), or are deemed affiliates (as such term is defined under the Exchange Act) with respect to such obligations or the transactions contemplated by this Agreement. Each Purchaser shall be entitled to
independently protect and enforce its rights, including the rights arising out of this Agreement, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. Each Purchaser
acknowledges (i)&nbsp;that it is not relying upon any Person other than the Company and its officers and directors, in making its investment or decision to invest in the Company and (ii)&nbsp;no other Purchaser has acted as agent for such Purchaser
in connection with making its investment hereunder and that no Purchaser will be acting as agent of such Purchaser in connection with monitoring its investment in the Securities or enforcing its rights hereunder. Each Purchaser agrees that no
Purchaser nor the respective controlling persons, officers, directors, partners, agents, or employees of any Purchaser shall be liable to any other Purchaser for any action heretofore or hereafter taken or omitted to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
be taken by any of them in connection with the purchase of the Securities. The Company acknowledges that each of the Purchasers has been provided with the same Agreement for the purpose of
closing a transaction with multiple purchasers and not because it was required or requested to do so by any Purchaser. It is expressly understood that each provision contained in this Agreement is between the Company and a Purchaser, solely, and not
between the Company and the Purchasers collectively and not between and among the Purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.11 <B>Payment of Fees
and Expenses.</B><B></B>&nbsp;Except as otherwise provided herein or in the other documents or instruments contemplated hereby, each of the Company and the Purchasers shall bear its own expenses and legal fees incurred on its behalf with respect to
this Agreement and the transactions contemplated hereby, except that the Company has agreed to pay the reasonable fees of Wilmer Cutler Pickering Hale and Dorr LLP, counsel for certain of the Purchasers, in an amount of up to $100,000, at the time
of Closing. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorney&#146;s fees, costs and necessary disbursements in addition to any other
relief to which such party may be entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.12 <B>Further Actions.</B>&nbsp;Each party hereto agrees to execute,
acknowledge, and deliver such further instruments, and to do all such other reasonable acts, as may be reasonably necessary or appropriate in order to carry out the purposes and intent of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.13 <B>Securities Law Disclosure.</B>&nbsp;By no later than 9:00 A.M., New York City time, on the Trading Day immediately
following the Effective Date (provided that, if this Agreement is executed between midnight and 9:00 A.M., New York City time on any Trading Day, no later than 9:01 A.M. on the Effective Date), the Company shall issue a press release and/or file a
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> with the Commission (the &#147;<B><I>Disclosure Document</I></B>&#148;) disclosing all material terms of the transactions contemplated by this Agreement; <I>provided</I>, that the
Purchasers shall be given a reasonable opportunity to review and comment on the disclosure contained in the Disclosure Document&nbsp;prior to filing). In addition, unless it has already done so by filing the Disclosure Document, on or before the
fourth (4<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) Business Day following the Effective Date, the Company shall file a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> with the Commission disclosing all material
terms of the transactions contemplated by this Agreement. From and after the issuance of the Disclosure Document, no Purchaser shall be in possession of any material <FONT STYLE="white-space:nowrap">non-public</FONT> information received from the
Company or from any other representative of the Company in connection with the transactions contemplated by this Agreement, except in the case of (i)&nbsp;information that may have been provided pursuant to any confidentiality agreement between the
Company and a Purchaser and (ii)&nbsp;information that may have been provided to a member of the Company&#146;s Board of Directors who is affiliated with such Purchaser, provided, that such information will no longer constitute material <FONT
STYLE="white-space:nowrap">non-public</FONT> information of the Company upon the earlier of the public release of such information by the Company and December&nbsp;31, 2024. Except for the Disclosure Document and the Current Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;contemplated</FONT> by this<U>&nbsp;Section</U><U></U><U>&nbsp;10.13</U>, all public announcements regarding this Agreement shall be issued only in accordance
with<U>&nbsp;Section</U><U></U><U>&nbsp;10.15</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.14<B> </B><B>Termination. </B>This Agreement (i)&nbsp;shall be
terminated at any time prior to Closing automatically if the Closing has not been consummated on or prior to the fifth Business Day from the Effective Date, or (ii)&nbsp;may be terminated by a Purchaser (with respect to itself) if any of the
conditions set forth in Section&nbsp;3.2(a) or Section&nbsp;3.2(b) shall have become incapable of fulfillment, and shall not have been waived by such Purchaser, <I>provided, however</I>, that no such termination will affect the right of any party to
sue for any breach by the other party (or parties), and, upon such termination pursuant to this <U>Section</U><U></U><U>&nbsp;10.14</U>, any purchase price wired to the Company by a Purchaser shall be promptly returned to the Purchaser, but in no
event later than the first Trading Day following such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.15 <B>Public Announcement.</B>&nbsp;The Company
shall not publicly disclose the name of any Purchaser or investment adviser of any Purchaser, or include the name of any Purchaser or an Affiliate of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Purchaser without the prior written consent of such Purchaser (i)&nbsp;in any press release or marketing materials or (ii)&nbsp;in any filing with the Commission or any regulatory agency or
Trading Market, except as required by U.S. federal securities law (A)&nbsp;in connection with any Registration Statement contemplated by this Agreement and (B)&nbsp;to the extent such disclosure is required by law, request of the Commission&#146;s
staff or Trading Market regulations, in which case the Company shall provide the Purchasers with prior written notice of and an opportunity to review such disclosure permitted under this subclause (ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[<SMALL>SIGNATURE</SMALL> <SMALL>PAGES</SMALL> <SMALL>FOLLOW</SMALL>] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to
be executed by their duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">COMPANY:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TYRA BIOSCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Todd Harris</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Todd Harris</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to
be executed by their duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PURCHASER:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Form of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D&amp;O <FONT STYLE="white-space:nowrap">Lock-up</FONT> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tyra Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">February&nbsp;1, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Tyra
Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2656 State Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Carlsbad, CA 92008 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re: <U>Tyra Biosciences, <FONT STYLE="white-space:nowrap">Inc.&#151;Lock-Up</FONT> Agreement</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned understands that Tyra Biosciences, Inc. (the &#147;<B><I>Company</I></B>&#148;) is entering into a Securities
Purchase Agreement dated on or about the date hereof (the &#147;<B><I>Purchase Agreement</I></B>&#148;) providing for the sale and issuance of shares of the Company&#146;s Common Stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants
to purchase shares of the Company&#146;s Common Stock. Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In consideration of the entry into the Purchase Agreement, and of other good and valuable consideration the receipt and
sufficiency of which is hereby acknowledged, the undersigned agrees that, during the period beginning on the date hereof and continuing to, and including, the date 60 days after the date of the Purchase Agreement (the &#147;<B><I><FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#148;), the undersigned shall not, without the prior written consent of the Company, subject to the exceptions set forth below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of the Company&#146;s Common Stock or any securities convertible into or exercisable or exchangeable for the Company&#146;s
Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (the
&#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT></I></B><B><I></I></B><B><I>&nbsp;Shares</I></B>&#148;), or publicly disclose the intention to make any offer, sale, pledge or disposition of any
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Shares; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(2) enter into any swap or other agreement that transfers, in
whole or in part, any of the economic consequences of ownership of <FONT STYLE="white-space:nowrap">the&nbsp;Lock-Up&nbsp;Shares,</FONT> whether any such transaction described in clause (1)&nbsp;above or this clause (2)&nbsp;is to be settled by
delivery <FONT STYLE="white-space:nowrap">of&nbsp;Lock-Up&nbsp;Shares</FONT> or such other securities, in cash or otherwise, in each case other than: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(A) transfers of <FONT STYLE="white-space:nowrap">the&nbsp;Lock-Up&nbsp;Shares</FONT> as a bona fide gift or
gifts, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(B) transfers or dispositions of
<FONT STYLE="white-space:nowrap">the&nbsp;Lock-Up&nbsp;Shares</FONT> to any trust for the direct or indirect benefit of the undersigned, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(C) distributions by a trust to its beneficiaries, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(D) transfers or dispositions of <FONT STYLE="white-space:nowrap">the&nbsp;Lock-Up&nbsp;Shares</FONT> to any
corporation, partnership, limited liability company or other entity, all of the beneficial ownership interests of which are held by undersigned, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(E) transfers or dispositions of <FONT
STYLE="white-space:nowrap">the&nbsp;Lock-Up&nbsp;Shares</FONT> by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of undersigned, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(F) transfers of <FONT STYLE="white-space:nowrap">the&nbsp;Lock-Up&nbsp;Shares</FONT> to partners, members or
stockholders of the undersigned, or to another partnership, limited liability company, corporation or other business entity that controls, is controlled by or is under common control with the undersigned; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(G) if the undersigned is an investment company registered under the Investment Company Act of 1940, as amended
(a &#147;<B><I>Mutual Fund</I></B>&#148;), pursuant to a merger or reorganization with or into another Mutual Fund that shares the same investment adviser registered pursuant to the requirements of the Investment Advisers Act of 1940, as amended;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(H) any transfers pursuant to a bona fide third-party tender offer, merger, consolidation or other similar
transaction, approved by the Board of Directors of the Company, made to all holders of Common Stock involving a change of control of the Company, provided that, in the event that such tender offer, merger, consolidation or other similar transaction
is not completed, any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock held by the undersigned shall remain subject to the restrictions on transfer set forth herein; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(I) transfers to the Company as forfeitures to satisfy tax withholding and remittance obligations of the
undersigned in connection with the exercise or vesting of equity awards granted pursuant to the Company&#146;s equity incentive plans or transfers to the Company pursuant to a net exercise or cashless exercise by the stockholder of outstanding
equity awards pursuant to the Company&#146;s equity incentive plans; provided the Common Stock issued shall remain subject to the restrictions on transfer set forth in this agreement and any filing under Section&nbsp;16 of the Exchange Act made
during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(J) transfers to the Company pursuant to any contractual arrangement that provides for the repurchase by the
Company or forfeiture of the undersigned&#146;s Common Stock in connection with the termination of the undersigned&#146;s service to the Company; provided that if the undersigned is required to file a report under Section&nbsp;16 of the Exchange Act
reporting a reduction in beneficial ownership of shares of Common Stock during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, the undersigned shall clearly indicate in the footnotes thereto that the filing relates to the termination of
the undersigned&#146;s employment or other services; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided that (x)&nbsp;in the case of any transfer or
distribution pursuant to clauses (A) &#150; (G), each transferee, donee or distributee shall execute and deliver to the Company <FONT STYLE="white-space:nowrap">a&nbsp;lock-up&nbsp;letter</FONT> in the form of this letter agreement; and (y)&nbsp;in
the case of any transfer, disposition or distribution pursuant to clause (A) &#150; (F), any such transfer or distribution shall not involve a disposition for value. For purposes of this agreement, &#147;immediate family&#148; shall mean any
relationship by blood, marriage or adoption, not more remote than first cousin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding anything herein to the
contrary, nothing herein shall prevent the undersigned from (a)&nbsp;establishing a <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plan that complies with Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act
(&#147;<B><I><FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan</I></B>&#148;) or from amending an existing <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan so long as there are no sales of Shares under such plan during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period; and provided that, the establishment of a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan or the amendment of a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan, in either
case, providing for sales of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Shares shall only be permitted if (i)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
regarding the establishment or amendment of such plan and (ii)&nbsp;if any filing under the Exchange Act or other public announcement shall be legally required during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period, such filing or public announcement shall indicate that no transfers under such trading plans will take place during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, or (b)&nbsp;selling <FONT
STYLE="white-space:nowrap">Lock-Up&nbsp;Shares</FONT> pursuant to a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan existing as of the date hereof provided that any required filing or report under the Exchange Act shall clearly indicate
in the footnotes thereto that such sales were made pursuant to a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This letter agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns
and is not for the benefit of, nor may any provisions hereof be enforced by, any other Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All authority herein
conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned understands that the undersigned shall be released from all obligations under this letter agreement if the
Purchase Agreement shall terminate or be terminated prior to the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This letter agreement and any claim,
controversy or dispute arising under or related to this agreement shall be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[signature page follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Very truly yours, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>IF AN INDIVIDUAL:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>IF AN ENTITY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>(duly authorized signature)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><I>(please print complete name of entity)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>(please print full name)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>(duly authorized signature)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>(please print full name)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>(please print full title)</I></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement] </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d620082dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g620082g0203021142421.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CARLSBAD, Calif., February</B><B></B><B>&nbsp;2, 2024</B> &#150; Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on
developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,&nbsp;announced today that it has entered into a securities purchase agreement with institutional and accredited
investors to sell securities in a private placement financing (the PIPE) for gross proceeds of approximately $200&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financing was led by
RA Capital Management, with participation by new and existing institutional investors, including Boxer Capital, BVF Partners, Nextech Invest Ltd (on behalf of one or more funds managed by it), OrbiMed, 5AM Ventures, a large investment management
firm and a life-sciences focused institutional investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We appreciate the support of RA Capital and our outstanding group of current and new
investors as we further our mission of developing next-generation precision medicines that target FGFR biology,&#148; said Todd Harris, CEO of TYRA. &#147;The additional funding strengthens our balance sheet at a time of strong momentum. We are
focused on developing <FONT STYLE="white-space:nowrap">TYRA-300,</FONT> an oral FGFR3-selective inhibitor, to become a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> agent for achondroplasia, NMIBC and
metastatic urothelial carcinoma, while advancing <FONT STYLE="white-space:nowrap">TYRA-200</FONT> and leveraging our SN&Aring;P platform to discover new drug candidates.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the PIPE, TYRA is selling an aggregate of approximately 15.4&nbsp;million shares of its common stock (or <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants in lieu thereof) at a price of $13.01 per share (or $13.009 per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant). The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will have an exercise price of $0.001 per share of
common stock, will be immediately exercisable and will not expire. The PIPE is expected to close on February&nbsp;6, 2024, subject to customary closing conditions. The financing was priced <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">at-the-market</FONT></FONT> under Nasdaq rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TYRA intends to use the net proceeds from the PIPE to advance the clinical
development of <FONT STYLE="white-space:nowrap">TYRA-300</FONT> and <FONT STYLE="white-space:nowrap">TYRA-200,</FONT> to advance its preclinical programs, and for drug discovery, working capital and general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold
in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. TYRA has agreed to file a registration statement with the Securities and Exchange
Commission (SEC) registering the resale of the shares of common stock and shares of common stock issuable upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants issued in this PIPE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Tyra Biosciences </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tyra Biosciences, Inc. (Nasdaq:
TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company&#146;s <FONT STYLE="white-space:nowrap">in-house</FONT> precision medicine
platform, SN&Aring;P, enables rapid and precise drug design through iterative molecular SN&Aring;Pshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
TYRA&#146;s initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in
Carlsbad, CA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information about our science, pipeline and people, please visit <U>https://tyra.bio/</U>and engage with us on <U>LinkedIn</U>.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TYRA cautions you that
statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to:
statements related to: the timing, size and expectation of the closing of the PIPE; expectations regarding market conditions, the satisfaction of customary closing conditions related to the PIPE and the anticipated use of proceeds therefrom; and the
potential to discover and develop next-generation precision medicines and develop a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> agent. Such forward-looking statements involve substantial risks and
uncertainties that could cause our actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a
representation by TYRA that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: the risks and
uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed financing; we are early in our development efforts and the approach we are taking to discover and develop drugs based on our
SN&Aring;P platform is novel and unproven and it may never lead to product candidates that are successful in clinical development or approved products of commercial value; and other risks described in our prior press releases and filings with the
SEC, including under the heading &#147;Risk Factors&#148; in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amy Conrad </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">aconrad@tyra.bio </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>tyra-20240201.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 2/5/2024 1:57:56 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:tyra="http://tyra.bio/20240201"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://tyra.bio/20240201"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tyra-20240201_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tyra-20240201_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>tyra-20240201_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 2/5/2024 1:57:56 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>tyra-20240201_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 2/5/2024 1:57:56 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="tyra-20240201.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g620082g0203021142421.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g620082g0203021142421.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  K ) # 2(  A$! Q$!_\0
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M]HEC8Q6Z# 1<?C7%^!;-);R>Y8 F, **[^ML)3M'F[G+FM=RJ>S6R/+O%O\
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0UPT?=K61[F,_>X/F?DS_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140554397269824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001863127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  01,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TYRA BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1476348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2656 State Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">728-4760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TYRA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *\P15@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "O,$58N*,/+^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>.FT9AZC+96BG(2$Q"<0M2KPMHDFCQ*C=VY.6K1."!^ 8^\_G
MSY);'83N(S['/F DB^EN=)U/0H<U.Q$% 9#T"9U*94[XW#STT2G*SWB$H/2'
M.B+4G#^ 0U)&D8()6(2%R&1KM- 1%?7Q@C=ZP8?/V,TPHP$[=.@I0556P.0T
M,9S'KH4;8((11I>^"V@6XES]$SMW@%V28[)+:AB&<FCF7-ZA@K>GW<N\;F%]
M(N4UYE_)"CH'7+/KY-=F\[C?,EGS^K[@=<%7^ZH2?"4:_CZY_O"[";O>V(/]
MQ\970=G"K[N07U!+ P04    " "O,$58F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M *\P15@Q7Q,5: 0  "@1   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MC9AK<^(V%(;_BL;M=-J9)+Y @*3 #''(EME=P@;:G;;3#\(6H(EMN9+,Y=_W
MR :;[9ICOH!EK->/CHY>'='?"?FN-HQILH^C1 VLC=;IHVVK8,-BJNY$RA+X
M925D3#4TY=I6J60TS#O%D>TY3L>.*4^L83^_-Y/#OLATQ!,VDT1E<4SEX8E%
M8C>P7.MTXXVO-]K<L(?]E*[9G.G?TYF$EEVJA#QFB>(B(9*M!M;(?7SR[DV'
M_(D_.-NILVMBAK(4XMTT)N' <@P1BUB@C02%KRWS6109)>#X]RAJE>\T'<^O
M3^HO^>!A,$NJF"^BKSS4FX'5LTC(5C2+])O8_<:. \H! Q&I_)/LBF?;CD6"
M3&D1'SL#0<R3XIONCX$X[^!=Z. =.W@Y=_&BG/*9:CKL2[$CTCP-:N8B'VK>
M&^!X8F9EKB7\RJ&?'CZ+((,@:T*3D(P3S?6!3))BMB%J?5O#2\RC=G 4?"H$
MO0N"+VQY1QSWAGB.U_ZVNPUL):!7 GJY7NN"GB^V3)*_1TNE)4SA/W5$A4*[
M7L'D]:-*:< &%B2N8G++K.%//[@=YU>$KU7RM3#UX0BB%^81?(GHNHX.[[^B
MD6((1[OD:*,ZQ[GS@432".8P9'ORD1WJB' EQW'<7J?E>ET$Z[[$ND?%ROQ:
M'%)6QX)W[]U^1" Z)43G.H@9DUR8/ \)K)9:'EPIS^X\O9ORNUNR=:^9MS>V
MYB;# 7)*XUHR7&?QY]N(/$U>Y_YD//7'\QLRF?IW"&"O!.Q= SA) B%3(7-;
M(',-X2.^R"#;(.E$6$N,"S^/$;J'DN[A&KH7'C$RS>(EDW4@N ;D^VW;Z3D.
MPN,ZE:$ZUQ MZ)Y,0D@ZON)!$;3+? V2O=:MV^YV6NT>1GAF^>XUA*,P!#M4
M-Z<+\@F>(Z])[50V2'J=^\XQ*> V;$88:&7]+NK<WX'ZIB4D68A=_<Z$R_E4
M1FI)0XRMLGT7]^W_LQ6#![B9%%N>!/51Q#7]$896[03N55M!B3832L.6\!=/
M+Z[4!L4'*/+0W*NV Q<W]'P*1U _7D;!!7[NN ^_8"C5IN#B7OY)!!"5V48D
MF'4TB'2]WBTL3=0ZJJW Q3W\J^1:LP1"$\=9<K0-54N%"S45%6YE_BYNTG,1
M\8!KGJS)9TAPR6E4RX.K-/)4=N_B7CV3+ \/@Q56U!50?D&!^+I:79@_7*^)
MS*M\W\--^CNRB5(9D#4!-L@V E:V[^$>/6=!)LWR<[TE67 =U2Z_!A$S0MC*
MX%P2O-^0E$JRI5'&R(_.G:D;20I#51LJ4>2SVA]W[(6DH4F]^2%>BMK$:Q*
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M> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( *\P15B7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ KS!%6!PX9>H_ 0
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M 5!+ 0(4 Q0    ( *\P15@'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ KS!%6+BC#R_N    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ KS!%6)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " "O,$58,5\3%6@$   H$0  &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ KS!%6)^@&_"Q @  X@P   T              ( !JPP  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " "O,$58EXJ[',     3 @  "P
M@ &'#P  7W)E;',O+G)E;'-02P$"% ,4    " "O,$58'#AEZC\!   \ @
M#P              @ %P$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MKS!%6"0>FZ*M    ^ $  !H              ( !W!$  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ KS!%6&60>9(9 0  SP,  !,
M             ( !P1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  "Q0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d620082d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d620082d8k.htm">d620082d8k.htm</File>
    <File>tyra-20240201.xsd</File>
    <File>tyra-20240201_lab.xml</File>
    <File>tyra-20240201_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d620082d8k.htm": {
   "nsprefix": "tyra",
   "nsuri": "http://tyra.bio/20240201",
   "dts": {
    "inline": {
     "local": [
      "d620082d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "tyra-20240201.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "tyra-20240201_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tyra-20240201_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-02-01_to_2024-02-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d620082d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-02-01_to_2024-02-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d620082d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://tyra.bio//20240201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-24-023367-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-023367-xbrl.zip
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M R063>V[01P"D-@/39< /2JUMS[BLJ''M886LWAB'F.<#V;.!#N7LADJB^*
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M:&99 25M70+[C:_6TH"UDYY4]SMKSB+7S*63=[:0MY3/_V*_A#%8NV"^A&#
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M-R(2$C[;HT2D5,8QD?<K;-H)!A]7$%838%_PSVY)5&?R*!>)J']<]3,G2VD
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ML0VM.IW;\#Q0 %-'#YETR^8^.9Q%5^2O%*^0R'P"A,P5>X9_R4 U^VSG#?#
M712)W!1CD;@!SY!G'L0#>@/W&O0Z6)3H9BE,E 5TB3*>A$I(F"@V %L/\0&
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MWNT,C>T!LV_9U-?%C!QH4*BT"&9\9/JADS3!= /X&V@=)W Z3O,U=\5IAI^
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M,ZHN8S49Z\2DS&ZLDI%H)'RZS]>L6+G.T RO&_@-6H>@#E:EUV*DD.%+-!A
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M>2! (5;07S5T_\V7T/W=ANZG(*&W>&0RB(8!@?90'<7)MWW?2_[$?1_LH-"
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M-E<X O$9+KF!%7E%]+GN#1?,VY02"+W_X86ORUG?:I6V*G:MV5;IV]OTT\#
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MBBW G,!HI&C<P2\C>C&3G!/7D4)U>RY,3K>*V<2YU5C[>!@_J%O5G\>0_;U
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M['*L&0HS\?M2"#JX*)@6^;XVN[7NU5QX2;L!DXFB3C=G7TQ/11'0[5HYA-$
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MT;$MA@06B19X^79Y1#B@/#YZ6:/\!%WKOJ>B(.R7WOB/AGKSV?LA%Q6.LXU
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M!?%#7P/+7EPH&*KE[0?#5>+<X>$^8HK<@OSCU=>GH ^GB3%2TU%-V8W]"#;
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M/(/; &<'1V+,.R(UD3$,Y$XTZZ1HC*//Q7*>E.H#B.9CM=B*.$_&DHAUGBE
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M9!RSC,#1 S%I=^K&6.Y>Y'ZHVL!3X[E^>DJ>4O+][%9]JRZ <3*T@+-BF<<
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M;8*HK!=C=@N2)9C/[084F!"\X<.$\\94%O?,[>A297NQ4-9A=SD&;,DRE4R
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MEGQ/G.744=$KI [QM F^B*:.R(P)P23S3EGHG9KZPJH2DS,*BEL*V\<%NO
M6YPG"-HBC,W7-MQWZ\@VPG3&P"0B3*JCHAZ&I.T^4.0GZAI*2F-FK4U\ME7O
MWOH&G5,A95&(]!?Q?,Z%X,Y%U(:'TQL,Q1BCQ7#H-/,PJH7V!4E_*JG1@WDY
MSAM:=Q&!7K'E"4>BLTJC3JA*C!W;H=L\"5]PZE[Z /,J /ADBXSU'HD1A0G4
M#>U)DUY$5K4DP1)OOM!S17H_5],?)D92D&FG]Y0.@B\N''"XZS>5#K:) L$F
M20"?NY*Y=3A1'CC)HY5SJI45VJW/$A;N+B+<<YEWDA=\Z?/.XH*:3%2!_VB)
MP06,QY4_3V20]+BMDH(W]>?("IM7?Q]AP0;@9\H*F!OW'R8LY :R% CO@DL>
M#96C""]--I]6A 7O-2TN<$"5R O5HU" _QIR0Z<(5CHC*BG<ZMZH/9/#33B8
M\-Y*<=9<2);BKK2SI780X^:HBCBA2V92_QJ+-L S%GOWZ\2CL5=65/^4M<#
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M/;-N1D>#-FA?<&-PI7H!O&NMRO<14QVJ4[E"=>T!"(4RNSHJA0QA!5NX3'#
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M<%DD8Y(J:VC01+8<$%HA#S&HEG+=V+4)&N2-(8.S& ,*Y^0*!"C,LXF*]#,
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MHHN'&TTH?K;_$0_YSY/^"U!+ P04    " "O,$58Z/F<&3@#   S"P  $0
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M0E(5NW#X-L?J<)YO>T1SJC!>&,]P07/JB9)I87&VH\E"HU(EH%I!O5[![W=
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MN^0Z.JA+#QOL4ZZ;(_:??6836_X%4$L! A0#%     @ KS!%6(8> /!(&P
MJ9@   X              ( !     &0V,C P.#)D.&LN:'1M4$L! A0#%
M  @ KS!%6(!O/)>KK0  1T<# !$              ( !=!L  &0V,C P.#)D
M97@Q,#$N:'1M4$L! A0#%     @ KS!%6$8U8P9>00  ,A@! !
M     ( !3LD  &0V,C P.#)D97@T,2YH=&U02P$"% ,4    " "O,$58[TP%
MR;(,  "E)   $0              @ ':"@$ 9#8R,# X,F1E>#DY,2YH=&U0
M2P$"% ,4    " "O,$58Z/F<&3@#   S"P  $0              @ &[%P$
M='ER82TR,#(T,#(P,2YX<V102P$"% ,4    " "O,$58(<9K@XL&  "H1@
M%0              @ $B&P$ ='ER82TR,#(T,#(P,5]L86(N>&UL4$L! A0#
M%     @ KS!%6)#L-4C+!   *RP  !4              ( !X"$! '1Y<F$M
F,C R-# R,#%?<')E+GAM;%!+!08     !P ' +T!  #>)@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>d620082d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tyra-20240201.xsd" xlink:type="simple"/>
    <context id="duration_2024-02-01_to_2024-02-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-01</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-334">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-02-01_to_2024-02-01"
      id="Hidden_dei_EntityCentralIndexKey">0001863127</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-345">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-346">2024-02-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-347">TYRA BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-348">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-349">001-40800</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-350">83-1476348</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-351">2656 State Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-352">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-353">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-354">92008</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-355">(619)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-356">728-4760</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-357">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-358">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-359">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-360">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-361">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-362">TYRA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-363">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-364">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2024-02-01_to_2024-02-01" id="ixv-365">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
